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Summary 
In the last two decades, substantial reductions particularly of P. falciparum malaria have been 
achieved world-wide and several countries are now aiming at malaria elimination. A changing malaria 
epidemiology in elimination settings requires adapting control strategies. A major challenge is the 
identification of asymptomatic parasite carriers, which constitute a major reservoir sustaining 
transmission and are often characterized by low parasite densities undetectable by microscopy. Gaps 
in knowledge of basic epidemiological parameters of asymptomatic and submicroscopic malaria 
infections in endemic settings, such as the infection rate or the duration of infection, further complicate 
the planning of control strategies. A second challenge is the control of P. vivax, which has proven 
more resilient to control measures because of its ability to form dormant liver stages. In Papua New 
Guinea (PNG), P. vivax prevalence is among the highest world-wide, but nonetheless P. falciparum 
has been the predominating parasite during the last decades. In recent years both P. falciparum and P. 
vivax have been successfully reduced in PNG and are now equally prevalent.  
In a first project, this thesis aimed to define the extent of submicroscopic malaria infections in PNG 
and Tanzania. Half of P. falciparum infections in both studies and half of P. vivax infections in PNG 
were not detected by microscopy. Applying two novel ultra-sensitive quantitative PCR (qPCR) assays 
to samples from a cross-sectional study in Tanzania revealed that a fifth of P. falciparum infections 
were even not detected using standard PCR. Gametocytes, the parasite stage transmitted from human 
to mosquito, were present in 40% of samples only detected by ultra-sensitive qPCR in Tanzania. A 
pilot study suggested the presence of such ultra-low density infections also in PNG. The extent of 
submicroscopic P. falciparum infections is thus substantially underestimated even using standard 
PCR. These results cast doubt on the usefulness of test-and-treat approaches for malaria elimination, 
which are inherently limited by the sensitivity of the diagnostic used.  
A second project of this thesis comprised a detailed analysis of patterns in P. falciparum and P. vivax 
infection and disease in school-aged children from PNG. Genotyping of P. falciparum and P. vivax 
infections allowed detecting super-infections also in chronically infected parasite carriers. Measuring 
the molecular force of infection (molFOI), i.e. the incidence of new infections in the blood, permitted 
quantifying exposure to P. falciparum and P. vivax on an individual level. Four out of five P. vivax 
infections were attributable to relapsing hypnozoites, stipulating inclusion of liver-clearing drugs in 
malaria interventions in PNG. More than 10-fold differences in molFOI between the participating 
villages demonstrated highly heterogeneous malaria transmission in the study area. Even between 
children from the same village, individual exposure ranged from none to 18 new clones/year for P. 
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falciparum and varied even more for P. vivax. This substantial heterogeneity in malaria transmission 
between neighboring villages, despite almost universal use of insecticide-treated bednets, presents a 
major challenge for future malaria control strategies in PNG. 
In PNG, the age group of children investigated in this thesis (5-10 years) is characterized by 
substantial semi-immunity particularly to P. vivax. Malaria episodes were therefore generally rare and 
more frequently due to P. falciparum despite a lower incidence of new clones compared to P. vivax. 
Higher exposure to P. falciparum reduced the risk of experiencing an episode relative to the number of 
infections received. However, children living in the highest endemic village still carried the main 
burden of P. falciparum episodes due to the higher total number of infections. A concurrent P. vivax 
infection decreased the risk of a P. falciparum episode. Age was associated with increasing protection 
against a P. vivax but not a P. falciparum episode, suggesting that heterogeneous transmission may 
abrogate the classical age trends observed previously for P. falciparum in PNG.  
The large majority of gametocyte carriers in these children were asymptomatic (79% for P. falciparum 
and 92% for P. vivax). Gametocytes of both species occurred less frequently in mixed P. falciparum/ 
P. vivax infections compared to single-single species infections. Treatment of asymptomatic P. 
falciparum and P. vivax infections is required to target the full gametocyte reservoir in PNG.  
Longitudinal tracking of individual parasite clones in two cohort studies in PNG children permitted 
estimating the duration of P. falciparum infections. Infections lasted on average 62 days and 38 days 
in settings of medium and high P. falciparum transmission, respectively. Within each study higher 
exposure was associated with longer infection duration. Infection duration did not change with age. 
Durations of natural P. falciparum infections in PNG children were much shorter than in similarly 
aged children from Ghana, which may reflect evolutionary adaptation of the parasite to a setting with 
differing seasonality. 
In conclusion, this thesis contributed basic and translational research for malaria surveillance: (i) 
Novel ultra-sensitive diagnostic assays for P. falciparum, designed for use on finger-prick blood 
samples, are a valuable tool for malaria surveillance. (ii) Parameters for investigating heterogeneity in 
malaria transmission were validated to inform surveillance response targeted to the local endemicity 
setting. (iii) Detailed data on patterns in malaria infection and disease in PNG children, on P. 
falciparum infection dynamics and on the P. vivax hynozoite reservoir can guide planning of future 
malaria interventions in PNG.       
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Introduction 
 
1.1  A brief overview of malaria epidemiology  
Malaria remains one of the most deadly diseases in developing countries, particularly in sub-
Saharan Africa, despite substantial gains in malaria control within the last two decades. In 2015, 3.2 
billion people remained at risk of malaria and 214 million new cases and 438’000 deaths were 
reported (World Health Organization, 2015a). Largely as a result of the massive roll-out of insecticide 
treated bednets (ITNs) to control the mosquito vector Anopheles spp., malaria incidence fell by 37% 
since the year 2000 (Bhatt et al., 2015; World Health Organization, 2015a). In the same period, the 
number of global malaria deaths per year was reduced by 48% (Bhatt et al., 2015; World Health 
Organization, 2015a). With 67% of malaria deaths reported world-wide, African children under the 
age of five still carry the main burden of malaria morbidity and mortality (Bhatt et al., 2015; World 
Health Organization, 2015a); however, malaria is no longer the leading cause of death in children in 
sub-Saharan Africa (Bhatt et al., 2015; World Health Organization, 2015a). Particularly outside of 
Africa and in countries moving towards malaria elimination, male adolescents or adults replace young 
children and pregnant women as most vulnerable groups owing to their high occupational risk of 
becoming infected (Cotter et al., 2013).   
Five species of the genus Plasmodium cause human malaria: P. falciparum, P. vivax, P. malariae, 
P. ovale and P. knowlesi. In Africa, P. falciparum is the strongly predominating parasite and 
responsible for the bulk of malaria-associated mortality and morbidity (Bhatt et al., 2015; Cameron et 
al., 2015). P. vivax is geographically more widespread (Battle et al., 2015; Gething et al., 2012) and 
less amenable to standard control measures aimed at P. falciparum, and thus considered the ultimately 
more challenging parasite for elimination (Cotter et al., 2013). Although traditionally regarded as the 
“benign” Plasmodium species,  P. vivax accounts for at least half of clinical malaria cases outside of 
Africa (World Health Organization, 2015a) and there is a growing body of evidence that also P. vivax 
can occasionally cause severe morbidity (Anstey et al., 2009; Price et al., 2007). P. malaria and, with 
more limited distribution, P. ovale are found mostly in sub-Saharan Africa and the Southwest Pacific, 
but are infrequently also observed in other parts of Asia and the Americas (Mueller et al., 2007a). P. 
malariae and P. ovale rarely cause clinical symptoms and are not reliably detected by microscopy or 
rapid diagnostic test (RDT), hence their true burden may be underestimated (Mueller et al., 2007a). A 
specific feature of P. vivax and P. ovale is their capability to form dormant liver stages, called 
hypnozoites, which can relapse weeks, months or even years after primary infection and are a major 
source of infection with these species (Robinson et al., 2015; White, 2011). In 2004, zoonotic P. 
knowlesi emerged as the fifth human malaria species and is capable of causing severe disease, 
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however, transmission so far remains restricted to the south-east Asian jungle (Millar and Cox-Singh, 
2015; Singh et al., 2004).             
1.2  Malaria diagnosis 
A variety of strategies and tools exist for clinical diagnosis of malaria and for measuring malaria 
endemicity. In countries currently in the control stage of malaria as well as in malaria-free countries, 
the focus lies on passive monitoring and managing of clinical malaria cases. However, as more and 
more countries have successfully reduced the burden of clinically patent malaria and aim at malaria 
elimination (World Health Organization, 2015a), control strategies will need to shift towards active 
surveillance-response for detection of asymptomatic parasite carriers (Bousema et al., 2014).  
Especially in resource-limited field settings, light microscopy (LM) and malaria RDT are the 
most commonly used tools for differential diagnosis of febrile illness and for generation of malaria 
prevalence data within national control programs. LM examination of giemsa-stained thick and thin 
blood smears allows species differentiation of malaria parasites, and can detect >10 parasites/µl blood 
in when performed by expert microscopists in European reference laboratories (Bejon et al., 2006). In 
field laboratories or when performed by less-trained personnel, however, sensitivity of LM is 
considerably reduced and infections below 200 parasites/µl blood are often undetected 
(Wongsrichanalai et al., 2007). The development of RDTs in the 1990s, which detect one or more of 
the Plasmodium antigens histidine-rich proteins 2 (HRP2), lactate dehydrogenase (pLDH) or aldolase 
by lateral-flow immuno-chromatography, has facilitated routine and point-of-care malaria diagnosis 
also in remote field settings. Stability of RDTs in the field has improved over the last decade and their 
sensitivity now is comparable to that of field microscopy (Bell et al., 2006; World Health 
Organization, 2015b), but especially detection of non-falciparum species remains problematic at 
densities below 200 parasites/µl blood (World Health Organization, 2015b). Higher parasite 
prevalence by RDT over LM in community surveys indicates better performance of RDTs compared 
to LM (Andrade et al., 2010; Fançony et al., 2013; Mwingira et al., 2014), however, the accuracy of 
RDT test results can be compromised by several factors such as residual P. falciparum HRP2 
circulating in the hosts’s blood after parasite clearance (Bell et al., 2005), high expression of pLDH in 
mature P. falciparum gametocytes (Mueller et al., 2007b), and deletion of hrp2 in areas of South 
America (Gamboa et al., 2010).      
Molecular methods based on amplification of parasite DNA or RNA can detect parasite densities 
around or below 1 parasite/µl blood (reviewed in chapter 2) and can reliably discriminate Plasmodium 
species also in mixed-species infections (Mueller et al., 2009). The wider application of molecular 
detection methods in epidemiological studies in recent years allowed estimating the extent of the 
previously undetected submicroscopic malaria infection reservoir (Cheng et al., 2015; Okell et al., 
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2009, 2012). Mathematical modeling predicts that in low-transmission settings, submicroscopic P. 
falciparum infections make up 80% of all malaria infections and contribute 40% of malaria 
transmission (Okell et al., 2012), underlining their relevance for successful control programs. Also for 
P. vivax, submicroscopic infections are particularly prevalent in low-transmission areas and on 
average 67% of infections are not detected by LM (Cheng et al., 2015).  
The majority of molecular methods for malaria diagnosis amplify parasite DNA using polymerase 
chain reaction (PCR) (e.g. Snounou et al., 1993) or loop-mediated isothermal amplification (LAMP) 
(Polley et al., 2010). While PCR-based methods such as nested PCR (nPCR) or quantitative PCR 
(qPCR) surpass LAMP in sensitivity and, in case of qPCR, allow quantification of parasite load in the 
sample (reviewed in chapter 2), they require a more advanced laboratory infrastructure and are thus 
less applicable in the field compared to LAMP. Similarly, methods for detection of parasite RNA such 
as (quantitative) reverse transcription PCR (qRT-PCR) (Wampfler et al., 2013) or nucleic acid 
sequence based amplification (NASBA) (Schoone et al., 2000) reach highest sensitivities but require 
stringent laboratory practices to avoid sample degradation and cross-contamination, and thus only 
have limited application in field settings. Recently, high-volume blood sampling has increased the 
sensitivity of DNA-based methods to that of RNA-based detection, revealing a much larger 
submicroscopic infection reservoir than previously anticipated (Imwong et al., 2015a, 2015b).  
Detection of anti-malarial antibodies in exposed hosts using enzyme-linked immunosorbent assay 
(ELISA) are promising for use in post-elimination settings as they can sensitively assess past exposure 
to malaria (malERA Consultative Group on Diagnoses and Diagnostics, 2011).  
1.3  Gametocyte detection 
Gametocytes are the sexual parasite stage responsible for human-to-mosquito transmission 
(Figure 1). When ingested by a mosquito, male and female gametocytes mature and fuse in the 
mosquito midgut, forming a zygote that develops into an ookinete and subsequently oocyst, which 
eventually gives rises to thousands of mosquito-to-human infective sporozoites. Detection of 
gametocytes is mainly used to (i) investigate in epidemiological studies the transmission potential of 
infections, and (ii) to measure post-treatment gametocyte carriage in clinical trials of anti-malarials to 
evaluate their direct transmission-reducing effect.  
Gametocyte detection by LM is problematic especially for P. vivax. This is because of generally 
low parasite densities in natural P. vivax infections and the morphological resemblance of P. vivax 
gametocytes and late trophozoites, leading to misclassification of scarce P. vivax gametocytemia 
(World Health Organization, 2010a). Despite the distinct crescent shape of P. falciparum mature 
gametocytes (World Health Organization, 2010a), LM is limited in detecting low-density 
gametocytemia also for P. falciparum. Molecular methods for detection of P. vivax and P. falciparum 
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gametocyte-specific RNA by qRT-PCR or quantitative NASBA (QT-NASBA) are at least 50-fold 
more sensitive than LM, and their application in field studies has revealed substantial submicroscopic 
gametocyte carriage for both species (Babiker et al., 1999; Beurskens et al., 2009; Koepfli et al., 
2015a; Ouédraogo et al., 2007, 2010; Schneider et al., 2004; Shekalaghe et al., 2007; Wampfler et al., 
2013). Of the 250 to 300 transcripts that are specifically expressed at different stages of gametocyte 
development in P. falciparum (Lasonder et al., 2002; Silvestrini et al., 2005; Young et al., 2005), the 
most commonly targeted transcript for detection of P. falciparum gametocytes in field studies is the 25 
kDa ookinete surface antigen (pfs25) mRNA. Pfs25 is highly and exclusively expressed in female 
stage V P. falciparum gametocytes (Tao et al., 2014; Young et al., 2005) and its mRNA is relatively 
stable even when blood is collected on filter paper (Jones et al., 2012; Pritsch et al., 2012). Orthologs 
of pfs25 are present in other Plasmodium spp. including P. vivax, which can be targeted for detection 
of species-specific gametocytes (Beurskens et al., 2009; Mens et al., 2006; Wampfler et al., 2013).  
 
 
Figure 1. The Plasmodium life cycle and measures of transmission. Entomology remains 
the gold standard, but molecular parameters are easier assessed in epidemiological studies 
and hence serve as surrogate markers. EIR, entomological inoculation rate; molFOI, molecular 
force of infection (chapter 1.5).  Figure adapted from Boddey and Cowman, 2013. 
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Application of sensitive molecular methods for gametocyte detection has revealed that 
submicroscopic P. falciparum gametocyte densities are sufficient to infect mosquitoes, albeit at lower 
rates than LM-detectable gametocyte densities (Bousema et al., 2012; Churcher et al., 2013; Lin 
Ouédraogo et al., 2016; Ouédraogo et al., 2009; Schneider et al., 2007). Proving the presence of 
infectious gametocytes undetectable even by molecular methods, a recent study in Burkina Faso 
showed that 10% of P. falciparum infections without any molecularly detectable gametocytes resulted 
infected mosquitoes (Lin Ouédraogo et al., 2016). Absence of detectable gametocytes thus does not 
exclude onward transmission of an individual malaria infection to mosquitoes. Nonetheless, 
investigating factors associated with gametocyte carriage in molecular epidemiologic studies allows 
identifying high-risk reservoirs of transmission.   
1.4  Genotyping of malaria infections 
Individual malaria clones can be distinguished in natural infections by genotyping of length-
polymorphic markers. Parasite genotyping is widely applied in malaria research, mainly in clinical 
efficacy trials of new anti-malarials and for molecular monitoring of control interventions. For clinical 
trials in endemic settings, where people are frequently infected and recurrent parasitemia shortly after 
treatment is commonly observed, comparing parasite genotypes in pre- and post-treatment blood 
samples is crucial to distinguish treatment failures from new infections after treatment (Borrmann et 
al., 2008; World Health Organization, 2008).  
For monitoring of malaria control interventions, parasite genotyping allows investigating parasite 
population structure (Al-Hamidhi et al., 2014; Bakhiet et al., 2015; Delgado-Ratto et al., 2014; 
Jennison et al., 2015; Koepfli et al., 2015b) as well as determining the multiplicity of infection (MOI), 
i.e. the number of concurrent clones in a blood sample. MOI has been discussed as a metric for 
measuring transmission, as the number of co-infecting clones is thought to increase with transmission 
intensity (Arnot, 1998; Beck et al., 1997; Ntoumi et al., 1995). MOI has also been explored as 
surrogate marker of anti-malarial immunity because of its age-dependence (Arnot, 1998; Falk et al., 
2006; Felger et al., 1999; Mueller et al., 2012; Smith et al., 1999a). Investigating MOI in field studies 
can therefore potentially help to understand patterns in disease risk. In young children in Tanzania, 
each additional clone increased the risk for symptomatic malaria episodes (Henning et al., 2004), 
whereas in older children high MOI seemed to protect from severe malaria and serves as a proxy for 
exposure (Beck et al., 1997; Genton et al., 2008a; Henning et al., 2004; Manning et al., 2011).  
The most commonly used length-polymorphic markers for genotyping of P. falciparum are the 
genes encoding for the merozoite surface proteins 1 and 2 (msp1 and msp2) and the glutamate-rich 
protein (glurp) (Snounou and Beck, 1998; World Health Organization, 2008). Also for P. vivax, 
fragment 3 of the msp1 gene (msp1F3) is one of the most size polymorphic and widely used markers 
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(Koepfli et al., 2009). Amplification of these markers by nPCR allows highly sensitive discrimination 
of parasite clones, which differ in the number of intra-genic repeats and hence length of the amplified 
PCR product. The adoption of capillary electrophoresis (CE) for sizing of PCR products made 
genotyping of large sample-sets feasible. CE achieves single base pair (bp)-resolution of sizing and 
allows clear discrimination of allelic families (Falk et al., 2006; Koepfli et al., 2009; Schoepflin et al., 
2009).  
Marker diversity is measured by calculating the expected heterozygosity (He),  i.e. the probability 
that two alleles randomly drawn from a population sample are different (Nei Masatoshi, 1987), 
according to !" = $$ − 1 ∙ 1 − ()*  
where n is the number of samples and pi the frequency of allele i. He increases with endemicity along 
with the number of detected alleles (Schoepflin et al., 2009). In medium- to high-endemic settings, He 
of Pf-msp2, Pf-msp1 and Pv-msp1F3 ranges between 0.9 and 1 at reasonable sample sizes (Koepfli et 
al., 2009, 2011a; Schoepflin et al., 2009), and thus chances that two co-infecting clones carry the same 
allele are usually less than 10%. However, presence of predominant alleles in a population can 
severely decrease the discriminatory power of genotyping markers especially in low-transmission 
settings.  
1.5  Molecular force of infection (molFOI) 
The force of infection (FOI) describes the number of new malaria infections acquired over time, 
i.e. the infection incidence. FOI is challenging to assess in endemic settings with high Plasmodium 
prevalence, where individuals often carry chronic and asymptomatic infections that complicate 
detection of super-infections. FOI can be assessed in treatment-to-reinfection cohorts by measuring the 
time until initially parasite-free participants are re-infected, or by fitting mathematical models to repeat 
cross-sectional prevalence data (Smith et al., 2010). Recently, high-resolution parasite genotyping in 
longitudinal cohorts allowed assessing the molecular force of infection (molFOI), i.e. the number of 
new genetically distinct parasite clones observed in the peripheral blood over time (Koepfli et al., 
2013; Mueller et al., 2012). molFOI can be measured in any longitudinal cohort and in spite of pre-
existing infections in the host. For P. falciparum, molFOI is closely related to the number of infections 
received from mosquitoes, however, cannot provide information about infections that are controlled 
before or within the liver. For P. vivax, clones observed in the blood stream can originate either from 
an infective mosquito bite or a relapsing hynozoite from the liver. P. vivax molFOI is hence referred to 
as force of blood-stage infection (molFOB) (Koepfli et al., 2013).  
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In a cohort study of 1-4 year old children from Papua New Guinea (PNG), P. falciparum and P. 
vivax molFOI/molFOB accurately depicted the risk of infection: they exhibited strong seasonality, were 
dependent on bednet usage and for P. falciparum also on age (Koepfli et al., 2013; Mueller et al., 
2012). P. falciparum molFOI was the strongest predictor of individual risk for a P. falciparum episode 
in these children (Mueller et al., 2012). Higher P. vivax molFOB, compared to P. falciparum molFOI, 
illustrated the higher exposure of young PNG children to diverse P. vivax over P. falciparum parasites 
despite comparable parasite prevalence (Koepfli et al., 2013).  
Due to the high sensitivity of molecular techniques, molFOI may provide a more accurate measure 
of mosquito-to-human transmission (Figure 1) than the traditional gold standard, the entomological 
inoculation rate (EIR), especially in settings of low or heterogeneous transmission (Hay et al., 2000; 
Tusting et al., 2014). Since molFOI can only be determined in longitudinal cohort studies, its wide-
spread application in malaria control programs may be limited; however, it is a valuable parameter for 
validation of more common and easier obtainable parameters such as parasite prevalence.  
1.6  Detectability and dynamics of natural malaria infections   
Infection dynamics describe the course of malaria infections longitudinally and investigate 
influencing factors. The two main parameters of malaria infection dynamics are the acquisition rate of 
new infections (closely related to molFOI/molFOB, chapter 1.5), and the clearance rate of persisting 
infection, which is inversely correlated to the duration of infection (Felger et al., 2012).  
Studying the course of natural malaria infections in endemic settings is complicated by several 
factors. The majority of malaria infections in endemic areas remain asymptomatic and will go 
undetected unless communities are actively screened for parasites, since infected hosts will not seek 
diagnosis and treatment in absence of symptoms. In addition, molecular diagnosis is required for 
identification of submicroscopic carriers (chapter 1.2). In areas of high transmission and frequent 
super-infection, monitoring parasite positivity only cannot provide information on the underlying 
dynamics of clonal infections (Bruce et al., 2000a, 2000b). Super-infecting parasite clones can only be 
identified using parasite genotyping, and longitudinal tracking of clones is further complicated by their 
imperfect detectability. Imperfect detectability of clones has been observed in individual blood-
samples as well as in longitudinal cohorts, in which clones can be intermittently absent before 
reappearing in later blood samples (Bretscher et al., 2010; Daubersies et al., 1996; Farnert et al., 1997; 
Felger et al., 2012; Koepfli et al., 2011b). Imperfect detectability is attributable to periodical 
sequestration of synchronized P. falciparum clones, leading to absence of parasites from the peripheral 
blood at the time of sampling, or fluctuating parasite densities around the detection threshold of PCR. 
The detectability of a clone hence largely depends on its density in the host’s blood, which in turn is 
controlled by the immune system of the host (Doolan et al., 2009). Adjusting for imperfect 
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detectability using mathematical models is therefore crucial for studying the dynamics of natural 
infections in semi-immune inhabitants of endemic areas (Felger et al., 2012; Sama et al., 2005; Smith 
and Vounatsou, 2003; Smith et al., 1999b).  
Investigating the dynamics of natural malaria infections thus requires longitudinal cohort studies 
in endemic settings with repeated sampling, the application of technically advanced molecular 
diagnostics, and sophisticated mathematical analyses. The complexity and cost of such studies likely is 
one of the reasons why, to this date, some of the most detailed data on the course and duration of 
malaria infections derives from treatment of neurosyphilis patients by deliberate malaria infection in 
the pre-antibiotic era (“malaria-therapy”; Collins and Jeffery, 1999a, 1999b; Jeffery and Eyles, 1955). 
Yet opposed to natural infections in endemic settings, in malaria-therapy the exact time of infection as 
well as inoculation material is known. The hospitalized patients were easily accessible to researchers 
and close monitoring of parasitemia was guaranteed. Malaria-therapy patients were usually malaria-
naïve and often treated with sub-curative doses of anti-malarial. In addition, no super-infections 
occurred in this clinical setting, which might alter the course of a pre-existing infection. Therefore, the 
relevance of malaria-therapy data for natural P. falciparum infections in endemic settings is 
questionable. 
 1.7  A unique place for malaria research: Papua New Guinea  
1.7.1  History of malaria control in PNG 
Four of the five human-infecting Plasmodium species are found in the highland and lowland areas 
of Papua New Guinea (PNG), namely P. falciparum, P. vivax, P. ovale and P. malariae (Müller et al., 
2003). Malaria endemicity varies strongly throughout the country, which is mainly due to differences 
in temperature depending on altitude. The principal malaria vector in PNG are mosquitoes of the 
Anopheles punctulatus group, but a variety of other species also contribute to transmission and species 
composition varies across the country (Cooper et al., 2009). In the costal lowlands, transmission is 
perennial with limited seasonal variation, whereas the highlands are low-endemic and characterized by 
sporadic outbreaks of malaria (Betuela et al., 2012a; Müller et al., 2003).  
Malaria control programs in PNG were initially based on indoor residual spraying (IRS) using 
dichloro-diphenyl-trichloroethane (DTT) in the 1960s to 1970s, which was eventually combined with 
mass drug administration using chloroquine (CQ) or amodiaquine (AQ). Cessation of IRS in the 1980s 
lead to a massive resurgence especially of P. falciparum, which replaced P. vivax as the most 
prevalent parasite (Mueller et al., 2005). First CQ-resistant P. falciparum and P. vivax parasites were 
observed in 1976 and the late 1980s, respectively, and by the mid 2000s resistance was frequently 
detected also against combination therapy of CQ or AQ plus sulfadoxine-pyrimethamine (SP) 
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(Karunajeewa et al., 2008; Marfurt et al., 2007). Along with the release of artemisinin-based 
combination therapies (ACT), this emergence of drug-resistance prompted a change of first line 
treatment of uncomplicated malaria in PNG to artemether-lumefantrine (AL), in addition with 
Primaquine (PQ) in case of uncomplicated P. vivax malaria (Papua New Guinea National Department 
of Health, 2009; World Health Organization, 2010). However, PQ causes hemolysis in individuals 
with glucose-6-phosphatase dehydrogenase (G6PD)-deficiency (Alving et al., 1956), for which a 
reliable and affordable point-of-care test is lacking. Futhermore, PQ is not readily available at the 
majority of health facilities in PNG (Pulford et al., 2013) and thus a large proportion of P. vivax 
malaria in PNG is not adequately treated.    
 
Figure 2. Age-standardized malaria prevalence by LM across PNG in 
2008/2009. (A) P. falciparum prevalence. (B) P. vivax prevalence. Relevant study 
sites for this thesis are marked with black stars. Figure modified from Hetzel et al., 
2015. 
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In 2004, a grant by the Global Fund to fight AIDS, Tuberculosis and Malaria allowed to re-
intensify malaria control efforts in PNG, supporting the countrywide distribution of 2.3 million long-
lasting insecticide treated bednets (LLIN) until 2009 (Hetzel et al., 2012). Since 2009, a follow-up 
Global Fund Round 8 grant supports continued free LLIN distribution (Hetzel et al., 2014), which 
resulted in 82% LLIN ownership and 48% LLIN usage by 2011 (Hetzel et al., 2014). As result, 
countrywide prevalence rates by LM dropped to 7% for P. falciparum, 4% P.vivax, 0.3% P. malariae 
and 0.4% P. ovale (Figure 2), which resembles parasite prevalence in the 1970 after massive IRS 
(Hetzel et al., 2015). In Madang province, where LM prevalences are comparable to the countrywide 
mean (7% each P. falciparum and P. vivax), PCR prevalences in the general population were reduced 
from 39% in 2006 to 19% in 2010 for P. falciparum and 32% to 13% for P. vivax (Arnott et al., 2013; 
Koepfli et al., 2015a; Schultz et al., 2010).      
1.7.2  Patterns of malaria infection and disease in PNG  
In settings where P. vivax and P. falciparum are co-endemic, parasite prevalence as well as 
symptomatic malaria episodes peak earlier in life for P. vivax than P. falciparum (Karyana et al., 2008; 
Luxemburger et al., 1996; Maitland et al., 1996; Phimpraphi et al., 2008). Differing mechanisms of 
anti-malarial immunity development, which remain enigmatic despite decades of intense research, 
may account for these differences. Also an increased exposure to P. vivax blood stage infections due to 
recurrent relapses, compared to P. falciparum, is often given as plausible cause (Koepfli et al., 2013; 
Robinson et al., 2015). In PNG children, clinical immunity to P. vivax is acquired rapidly: 
uncomplicated disease peaks in children younger than two years and P.vivax episodes are rarely 
reported in children older than five years (Betuela et al., 2012b; Genton et al., 2008b; Lin et al., 2010; 
Michon et al., 2007). In comparison, the risk of P. falciparum episodes increases during early 
childhood (Lin et al., 2010) and significant reductions are only observed in incidence of high-density 
infections (>5000 parasites/µl) and symptomatic episodes in young teenagers (Michon et al., 2007). 
Asymptomatic infections remain common until adulthood for both species in PNG, yet similar to 
disease patterns, overall P. vivax prevalence peaks at younger ages than P. falciparum prevalence 
(Mueller et al., 2009) (Figure 3). Prevalence patterns of P. malariae and P. ovale resemble those of P. 
falciparum with peak prevalence in older children and young adolescents for both species (Kasehagen 
et al., 2006; Mueller et al., 2007a). 
Because of sympatric transmission of four human Plasmodium spp. in PNG, mixed-species 
infections are common and several studies have tried to address potential effects of species interaction 
within the human host. However, patterns in the distribution of mixed-species infections in PNG are 
not clear, with some studies reporting random (Mehlotra et al., 2000, 2002) or non-random (Mueller et 
al., 2009) occurrence of mixed-species infections. Similarly, it remains unclear how infection with one 
species alters the risk of infection with another (Bruce et al., 2000c; Smith et al., 2001). A preceding 
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infection with P. vivax seemed to reduce the risk for P. falciparum episodes in one study (Smith et al., 
2001), but in contrary, PQ treatment and thus lower subsequent P. vivax carriage decreased the risk for 
P. falciparum episodes in another (Betuela et al., 2012b). A study in young PNG children described an 
increased mortality and risk for coma among severe malaria cases in patients carrying mixed P. 
falciparum/P. vivax infections compared to single-species infections (Manning et al., 2011). The 
effects of changing species composition and decreasing prevalence of mixed-species infections 
alongside successful malaria control programs thus remain difficult to predict.  
 
Figure 3. Age-stratified prevalence of P. falciparum and P. vivax in Madang province, PNG, in 
2010. The study took place at the beginning of the (moderate) dry season, roughly two years after 
LLIN distribution. Figure from Koepfli et al., 2015a. 
 
1.8  The Albinama cohort  
Several longitudinal cohort studies have been conducted in the last decade in different 
geographical settings and age groups in PNG to investigate the molecular epidemiology of 
Plasmodium spp.. This thesis closely revolves around the Albinama cohort, an interventional cohort 
conducted from 2009 to 2010 in Maprik district, East Sepik province (Figure 2), with the primary aim 
to quantify the contribution of P. vivax relapses to infection and disease in 5-10 year old PNG children 
(Robinson et al., 2015). Samples from an interventional cohort performed in 2004 in Mugil area, 
Madang province (“Mugil cohort”, Figure 2) (Michon et al., 2007) were analyzed in comparison to the 
Albinama cohort because of the similar age range of study participants. 
The Albinama cohort comprised an initial randomized radical cure treatment over four weeks with 
CQ and AL plus  PQ or placebo (Table 1), followed by 8 months of close active and passive follow-up 
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(Figure 4) (Robinson et al., 2015). At the beginning of the study, blood-stage parasites were hence 
cleared in all 504 study participants that completed initial treatment. One half of participants retained 
P. vivax hynozoites in the liver that could relapse during the follow-up period, while in the other half 
the liver was cleared of hypnozoites by intense PQ treatment. PQ was administered over four instead 
of two weeks (as recommended by WHO) to assure optimal liver clearance, which had not been 
achieved after two weeks of PQ treatment an earlier cohort in younger PNG children (Betuela et al., 
2012b).  
 
 
 
Figure 4. Albinama cohort study design, follow-up schedule and drug administration schedule. All 
doses of drug treatment were directly observed. Children were actively followed for clinical symptoms in 
two-weekly intervals throughout the study period, and actively monitored for infection every two weeks 
in the first 3 months of follow-up and monthy thereafter. Passive surveillance was provided throughout 
follow-up. PQ arm: Primaquine arm. PL arm: placebo arm. Figure modified from Robinson et al., 2015.  
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The age group covered by the Albinama cohort (5-10 years) complemented a previous 
observational cohort conducted in the same study area in younger children (1-4 years) for which 
detailed molecular epidemiological data exists (Koepfli et al., 2013; Lin et al., 2010; Mueller et al., 
2012). The close active as well as passive surveillance of participants in the Albinama cohort, in 
collaboration with local health centers and health volunteers in all participating villages, allowed 
registering of all malaria episodes during follow-up together with the type of treatment administered. 
The Albinama cohort was the first cohort study in PNG that employed specific sampling of blood for 
molecular detection of gametocytes at all follow-up visits, allowing longitudinal investigation of 
gametocyte dynamics. The Albinama study thus provides a unique framework for comprehensive, 
longitudinal and detailed analysis of molecular parasitological parameters, alongside demographic and 
clinical data for investigation of patterns in malaria infections, transmission and disease.   
 
Table 1. Parasite stage-specific effects of drugs used in the Albinama study. 
Drug 
           Effect on 
References 
P. falciparum P. vivax 
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 Gametocytes 
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CQ + (+) – + + – 
(Bousema and Drakeley, 2011; 
Pukrittayakamee et al., 2008; Smalley, 
1977; White, 2008) 
AL + + – + + – 
(Bousema and Drakeley, 2011; 
Eastman and Fidock, 2009; Makanga, 
2014; Okell et al., 2008; 
Pukrittayakamee et al., 2008; Sawa et 
al., 2013) 
PQ – – + – + + (Graves et al., 2015; Pukrittayakamee et al., 2004, 2008) 
–: no effect, +: effective clearance, (+): partially effective clearance 
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1.9  Aims and objectives of this thesis 
The aim of this thesis was two-fold: Firstly, to evaluate and improve the accuracy and precision of 
molecular methods for detection and genotyping of P. falciparum infections for use in epidemiological 
studies and malaria drug trials. Secondly, to assess patterns in molecular infection parameters of P. 
falciparum and P. vivax, as well as infection and transmission dynamics, in semi-immune PNG 
children to contribute to our understanding of malaria epidemiology and acquisition of anti-malarial 
immunity in PNG. 
The specific objectives of this thesis were as follows:         
Objective 1: Development of new ultra-sensitive assays for detection of P. falciparum infections 
a. To develop DNA-based qPCR assays that circumvent the drawbacks of high-volume sampling 
and RNA-based detection by targeting multi-copy sequences. 
b. To investigate the extent of ultra-low density infections in samples from PNG and in a cross-
sectional study in Tanzania. 
c. To explore the feasibility of sample pooling using ultra-sensitive detection assays.  
Objective 2: Comparative analysis of patterns in P. falciparum and P. vivax infection and disease 
in the Albinama cohort 
a. To determine molecular epidemiological parameters of malaria infection (prevalence, MOI, 
molFOI) using 18S rRNA qPCR, Pv-msp1F3 and Pf-msp2 genotyping. 
b. To quantify heterogeneity in molecular parameters of infection in the study population. 
c. To identify risk factors for malaria infection and symptomatic malaria episodes.  
d. To describe the relationship of molFOI and the incidence of malaria episodes. 
Objective 3: Modeling the dynamics of natural P. falciparum infections in school-aged PNG 
children  
a. To estimate detectability and clearance rates of P. falciparum msp2-clones in the Albinama 
and Mugil cohorts using the triplet model. 
b. To quantify the effect of imperfect detectability on estimates of clone acquisition rates.  
c. To investigate the relationship of surrogate markers of immunity and exposure, i.e. age and 
molFOI, with clone acquisition and clearance rates.  
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Objective 4: Investigating P. vivax and P. falciparum gametocyte carriage after radical cure 
(joint project with Rahel Wampfler, PhD) 
a. To quantify gametocyte carriage in submicroscopic and asymptomatic infections using pfs25 
and pvs25 qRT-PCR in the Albinama cohort. 
b. To assess gametocyte production in P. vivax relapses and new infections by comparison of 
treatment arms. 
c. To compare gametocyte carriage of P. falciparum and P. vivax infections and identify risk 
factors for gametocyte carriage.  
Additional project: Validation of the recommendend genotyping procedures for P. falciparum 
recrudescence typing in clinical trials 
a. To quantify the extent of amplification bias and minority clone detectability in P. falciparum 
msp1, msp2 and glurp PCR.  
b. To assess the effect of PCR multiplexing on amplification bias and minority clone 
detectability. 
c. To evaluate the accuracy of sequential typing versus obligate typing of all three markers for 
recrudescence typing using 44 paired anonymous field samples. 
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SUPPLEMENT 
 
 
S1 Table. Oligonucleotide sequences and qPCR conditions for varATS and TARE-2 assays. 
Primers were purchased from Eurofins. The varATS probe and all qPCR reagents were purchased 
from Applied Biosystems/Life Technologies. 
 varATS TARE-2 
Oligonucleotide sequences 
 Primer-fw (5’-3’) cccatacacaaccaaytgga ctatgttgcacttacatgcayaat 
 Primer-rev (5’-3’) ttcgcacatatctctatgtctatct tgacctaagaagtavaataatgatga 
 Probe (5’-3’) 6-FAM-trttccataaatggt-NFQ-MGB - 
qPCR reaction conditions (final concentration in qPCR mix) 
 Total volume 12 (25)$ 25 (25)$ 
 DNA volume 4 (5)$ 4 (5)$ 
 TaqMan® Gene Expression 
Mastermix 
1x - 
 Power SYBR® Green mix - 1x 
 Primer (each fw & rev) 800 nM 200 nM 
 Probe  400 nM - 
qPCR cycling conditions 
 Pre-incubation 2 min – 50°C 2 min – 50°C 
 Initial denaturation 10 min – 95°C 10 min – 95°C 
 Denaturation 15 sec – 95 °C 15 sec – 95 °C 
 Annealing & Elongation 1 min – 55°C 1 min – 57°C 
 Number of cycles 45 45 
 Melt Curve  - 57-95°C, 0.3°C increment 
Positivity threshold 0.07 0.07 
Standard material for 
quantification 
Plasmid gDNA of parasite dilution row 
Platform  StepOne Plus® Real-Time PCR 
System (Applied Biosystems) 
StepOne Plus® Real-Time PCR 
System (Applied Biosystems) 
$ Brackets: volumes used for sensitivity and specificity tests on parasite culture and for PNG samples. 
 
 
The remaining supplementary files can be downloaded from: 
http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001788#sec028 
 
These include:   
S2 Table. STARD checklist for reporting studies of diagnostic accuracy. 
S3 Table. Results of TARE-2, varATS, and 18S rRNA qPCRs on parasite dilution rows. 
S4 Table. Database of light microscopy and qPCR results of the Tanzanian cross-sectional study. 
S1 Text. Generation of P. falciparum dilution rows for determining the limit of detection and qPCR 
efficiency. 
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SUPPLEMENT 
 
Figure 1 – figure supplement 
Figure 1 – figure supplement 1: Definition of new infections for calculating molFOB. Definition of 
P. falciparum new infections in two exemplary children is shown. The study design and timelines of 
follow-up are shown in upper panel: enrolment visit (“E”), followed by radical treatment (black bar 
“T”) and 235 days of follow-up. The presence of P. falciparum clones by sampling visit is visualized 
below. Columns represent sampling visits, rows represent P. falciparum msp2 alleles, i.e. distinct P. 
falciparum clones. Grey solid circles, P. falciparum negative sample, grey open circle, missing sample 
due to missed follow-up visit; red circle: sample positive for respective Pf-msp2 allele. New infections 
were defined as a positive sample preceded by two samples negative for this allele (black rectangles), 
excluding missed samples (see Child 2, allele F, days 120-200). The time point of new infections is 
marked by arrows for the two children.  
 
 
Figure 1 – figure supplement 2: P. ovale and P. malariae prevalence by qPCR during follow-up. 
Purple lines, P. ovale; green lines, P. malariae; solid lines, Placebo arm; dashed lines, PQ arm. Open 
circles mark enrolment qPCR prevalence for each species. 
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Supplementary File 1 – Univariate factors 
 
Table 1. Univariate/PQ-adjusted predictors for time to recurrent blood-stage infection with Plasmodium species by qPCR. 
Variable 
P. vivax P. falciparum P. malariae P. ovale 
HR1 CI95 p-value HR1 CI95 p-value HR1 CI95 p-value HR1 CI95 p-value 
PQ treatment 0.27 0.20-0.36 <0.001 0.79 0.57-1.09 0.057 0.60 0.26-1.38 0.233 0.40 0.17-0.96 0.040 
Age 0.94 0.86-1.02 0.155 0.97 0.87-1.08 0.542 0.95 0.73-1.23 0.684 0.90 0.69-1.18 0.447 
LLIN use at enrolment 0.38 0.25-0.58 <0.001 0.44 0.27-0.72 0.001 0.77 0.18-3.28 0.724 0.51 0.15-1.70 0.271 
Hb at enrolment (g/dl) 0.81 0.73-0.89 <0.001 0.76 0.68-0.86 <0.001 0.66 0.50-0.87 0.003 0.78 0.58-1.04 0.087 
Village             
Albinama (ref) 1   1   1   1   Amahup 0.44 0.28-0.69 <0.001 0.55 0.29-1.05 0.068 0.32 0.06-1.67 0.178 2.57 0.27-24.73 0.414 
Balanga 2.23 1.46-3.39 <0.001 2.06 1.15-3.69 0.016 1.34 0.35-5.12 0.665 7.28 0.81-65.11 0.076 
Balif 0.96 0.63-1.50 0.843 0.57 0.29-1.12 0.101 0.21 0.02-1.79 0.153 4.13 0.46-36.92 0.205 
Bolumita 4.92 3.29-7.36 <0.001 6.79 4.15-11.12 <0.001 3.08 1.04-9.11 0.041 22.40 2.88-174.39 0.003 
Numangu 0.91 0.48-1.71 0.765 2.43 1.25-4.73 0.009 1.36 0.26-7.04 0.711 3.60 0.22-57.66 0.365 
Infection status at enrolment (by qPCR) 
Uninfected (ref) 1   1   1   1   
P. vivax 1.34 0.97-1.87 0.079 1.49 0.94-2.37 0.090 1.03 0.23-4.62 0.971 1.97 0.63-6.23 0.246 
P. falciparum 2.52 1.64-3.89 <0.001 3.11 1.77-5.46 <0.001 6.09 1.63-22.82 0.007 2.89 0.69-12.12 0.146 
P. malariae 1.37 0.63-2.98 0.426 1.74 0.68-4.45 0.250 9.81 2.17-44.38 0.003 2.63 0.31-22.63 0.378 
Mixed P.f. or P.v.2 3.39 2.37-4.87 <0.001 5.84 3.75-9.10 <0.001 6.64 2.03-21.72 0.002 5.50 1.79-16.88 0.003 
1 PQ treatment, univariate HR. All other HRs are adjusted only for PQ treatment. HRs were modeled using Cox proportional hazard regression. 
2 Mixed infection including P. falciparum or P. vivax infection in conjunction with one or more other Plasmodium spp. 
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Table 2. Univariate (P. vivax) and univariate/PQ-treatment-adjusted (P. falciparum) predictors 
for Pv- and Pf-molFOB by follow-up interval.  
Variable 
P. vivax P. falciparum 
PQ arm placebo arm Combined arms 
IRR1 CI95 p-value IRR1 CI95 p-value IRR2 CI95 p-value 
PQ treatment n.a.3 n.a. n.a n.a. n.a. n.a. 0.94 0.64-1.39 0.785 
New P. falc. 
infections in 
interval 
1.78 1.18-2.69 0.006 1.52 1.11-2.10 0.010 n.a. n.a n.a 
New P. vivax 
infections in 
interval 
n.a.  n.a n.a. n.a. n.a. n.a. 1.41 1.13-1.75 0.002 
Age 0.79 0.67-0.93 0.004 0.94 0.85-1.04 0.23 0.94 0.82-1.18 0.39 
LLIN at enrol. 0.58 0.32-1.02 0.060 0.50 0.34-0.74 <0.001 0.53 0.31-0.91 0.022 
Haemoglobin  at 
enrol. (g/dl) 
0.90 0.79-1.01 0.081 0.94 0.86-1.03 0.20 0.84 0.77-0.91 <0.001 
Village           
Albinama (ref) - - 
 
- - 
 
- - 
 Amahup 0.02 0.00-0.12 <0.001 0.50 0.30-0.83 0.007 0.52 0.2-1.06 0.072 
Balif 0.93 0.41-2.11 0.874 1.66 1.09-2.52 0.019 1.96 1.06-3.64 0.032 
Balanga 0.25 0.09-0.74 0.013 1.00 0.64-1.56 1.000 0.74 0.36-1.52 0.416 
Bolumita 1.98 1.05-3.78 0.036 3.18 2.19-4.59 <0.001 7.80 4.48-13.55 <0.001 
Numangu 0.46 0.14-1.54 0.213 0.75 0.40-1.44 0.391 2.85 1.45-5.62 0.002 
Study Day           
Day 0-35 (ref) - -     - - 
 Day 36-80 1.46 0.60-3.55 0.410 1.90 1.21-2.75 0.001 2.54 1.45-4.45 0.001 
Day 81-175 1.35 0.61-2.99 0.450 0.81 0.5-1.19 0.285 1.12 0.67-1.88 0.655 
Day >175 0.66 0.26-1.67 0.480 0.56 0.37-0.84 0.005 0.91 0.49-1.71 0.772 
1 P. vivax, stratified by treatment arm. Univariate IRRs were modeled per sampling interval using negative 
binomial generalized estimating equations allowing for repeated visits with log-link and an exchangeable 
correlation structure.  
2 P. falciparum, combined treatment arms. PQ treatment, univariate IRR. All other IRRs are adjusted only for PQ 
treatment. IRRs were modeled per sampling interval using negative binomial generalized estimating equations 
allowing for repeated visits with log-link and an exchangeable correlation structure.  
3 n.a., not applicable. 
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Table 3. Univariate/PQ-treatment-adjusted predictors for time to P. vivax and P. falciparum 
episodes. 
Variable 
P. vivax P. falciparum 
HR1 CI95 p-value HR1 CI95 p-value 
PQ treatment 0.50 0.21-1.56 0.11 1.72 1.01-2.93 0.04 
P. vivax molFOB3 1.07 1.05-1.09 <0.001 n.a. n.a. n.a. 
P. falciparum molFOB3 n.a. n.a. n.a. 1.18 1.15-1.21 <0.001 
Age 0.66 0.50-0.87 0.003 0.95 0.80-1.11 0.50 
LLIN at enrolment 0.88 0.21-3.60 0.86 0.45 0.22-0.96 0.038 
Hb at enrolment  (g/dl) 0.76 0.58-0.99 0.045 0.76 0.63-0.93 0.006 
Village       
Albinama (ref) - - - 1 - - 
Amahup 0.72 0.18-2.78 0.637 0.54 0.15-1.94 0.346 
Balif 1.50 0.45-5.02 0.506 0.96 0.29-3.19 0.949 
Balanga 0.68 0.16-3.02 0.617 1.25 0.47-3.36 0.656 
Bolumita 2.12 0.69-6.53 0.189 3.78 1.61-8.90 0.002 
Numangu 1.13 0.23-5.69 0.876 5.70 2.43-13.30 0.001 
Infection status at enrolment (by qPCR) 
Uninfected (ref) - - - - - - 
P. vivax 2.41 0.94-6.18 0.068 3.21 1.67-6.16 <0.001 
P. falciparum 0.88 0.33-2.36 0.806 1.41 0.72-2.78 0.319 
Mixed P.f. or P.v. 1.38 0.39-4.95 0.620 1.43 0.48-4.27 0.517 
1 PQ treatment, univariate HR. All other HRs are adjusted only for PQ treatment. AHRs were 
modeled using multiple failure Cox proportional hazard regression.  
2 n.a., not applicable 
3 Average molFOB until the time of failure (time-varying covariate).  
  
Chapter 3: Micro-geographical heterogeneity in malaria transmission in PNG 
 
80 
Published in eLIFE, 2017 
Table 4. Univariate/PQ-treatment-adjusted predictors for odds of P. falciparum clinical 
episodes. 
 
 P. falciparum episode 
Variable OR1 CI95 p-value 
PQ treatment 1.63 0.94-2.83 0.08 
P. vivax qPCR positive2 0.70 0.34-1.45 0.35 
P. falciparum molFOB 1.22 1.14-1.31 <0.001 
Age 0.89 0.76-1.06 0.20 
LLIN at enrolment 0.39 0.18-0.86 0.02 
Haemoglobin (g/dl) 0.97 0.85-1.11 0.68 
Village     
Albinama (ref) - -  Amahup 0.43 0.12-1.55 0.198 
Balif 0.94 0.27-3.31 0.925 
Balanga 1.34 0.46-3.85 0.592 
Bolumita 4.14 1.59-10.74 0.004 
Numangu 5.90 2.34-14.89 <0.001 
Study Day 
Day 0-80 (ref) - -  
Day 81-175 0.87 0.47-1.61 0.649 
Day >175 0.73 0.36-1.47 0.376 
1 PQ treatment, univariate OR. All other ORs are adjusted only for PQ 
treatment. ORs were modeled using a binomial generalized estimating 
equation with logit link function using an exchangeable correlation 
structure.  
2 Determined as P. vivax positive at the same or previous sampling visit. 
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Supplementary File 2 - Multivariable predictors for time to recurrent blood-stage infection with 
Plasmodium species by LM. 
 
Variable 
P. vivax P. falciparum 
AHR1 CI95 p-value AHR1 CI95 p-value 
PQ treatment 0.17 0.11-0.24 <0.001 0.76 0.50-1.17 0.216 
Age 0.85 0.77-0.95 0.004 1.16 1.01-1.33 0.037 
LLIN use at enrolment 0.76 0.45-1.30 0.319 0.56 0.31-1.02 0.056 
Hb at enrolment (g/dl) 0.86 0.76-0.97 0.18 0.78 0.67-0.91 0.002 
Village       
Albinama (ref) 1   1   
Amahup 0.35 0.19-0.63 0.001 1.19 0.44-3.20 0.736 
Balanga 1.49 0.88-2.51 0.139 3.17 1.24-8.12 0.016 
Balif 1.12 0.69-1.84 0.644 1.25 0.45-3.46 0.673 
Bolumita 3.38 1.97-5.82 <0.001 9.07 3.76-21.87 <0.001 
Numangu 0.59 0.25-1.35 0.208 5.93 2.27-15.50 <0.001 
Infection status at enrolment (by qPCR)  
Uninfected (ref) 1   1   
P. vivax 1.49 0.98-2.25 0.062 1.21 0.63-2.35 0.562 
P. falciparum 1.10 0.61-1.99 0.747 1.53 0.74-3.15 0.251 
P. malariae 1.28 0.53-3.11 0.575 0.87 0.25-2.99 0.828 
Mixed P.f. or P.v.2 1.94 1.18-3.21 0.009 2.24 1.18-4.23 0.013 
1 AHRs were modeled using Cox proportional hazard regression.  
2 Mixed infection including P. falciparum or P. vivax infection in conjunction with one or more 
other Plasmodium spp. 
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Supplementary file 3 - Multivariable predictors for P. falciparum and P. vivax density by qPCR 
during follow-up. 
 P. vivax density1 by qPCR  P. falciparum density1 by qPCR  
Variable exp(β)2 CI95 p-value exp(β)2 CI95 p-value 
PQ treatment 1.16 0.85-1.58 0.354 0.66 0.39-1.10 0.112 
Fever (>37.5°C axillary) 0.99 0.57-1.71 0.960 7.38 3.60-15.14 <0.001 
P. falc. molFOB n.a. n.a. n.a. 1.07 1.00-1.15 0.039 
P. vivax qPCR positive n.a. n.a. n.a. 0.45 0.25-0.81 0.008 
P. vivax molFOB 1.03 1.01-1.05 0.006 n.a. n.a. n.a. 
P. falc. qPCR positive 1.11 0.81-1.52 0.529 n.a. n.a. n.a. 
Age 0.90 0.83-0.98 0.016 0.96 0.80-1.14 0.645 
LLIN at enrol. 1.03 0.71-1.49 0.883 0.41 0.15-1.08 0.072 
Hb at enrolment (g/dl) 1.11 1.00-1.22 0.050 0.91 0.74-1.11 0.353 
Village       
Albinama 1   1   
Amahup 1.02 0.56-1.86 0.941 0.83 0.21-3.36 0.796 
Balif 0.99 0.71-1.37 0.933 1.26 0.38-4.14 0.707 
Balanga 0.71 0.49-1.03 0.071 3.35 0.78-14.43 0.104 
Bolumita 0.79 0.57-1.10 0.168 0.76 0.26-2.27 0.629 
Numangu 0.93 0.48-1.81 0.833 0.82 0.23-2.91 0.757 
Month of follow-up 0.77 0.73-0.82 <0.001 0.82 0.71-0.94 0.004 
1 Parasite densities by qPCR were assessed as 18S rRNA copy numbers/µl blood and log10 transformed.  
2 Estimates were obtained using gaussian generalized estimating equations with logit-link allowing for repeated 
visits.  
3 n.a., not applicable 
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Supplementary file 4 - Multivariable predictors of Pv-molFOB (combining primaquine and 
placebo arms) per follow-up interval. This model is similar to that presented in Table 4 in the main 
text but combines the treatment arms for P. vivax. Model predictions from this model were used for 
mapping molFOI in Figure 3B. 
Variable P. vivax (combined) 
  IRR1 CI95 p-value 
PQ treatment 0.27 0.2-0.36 <0.001 
New P. falc. infections in interval2 1.18 0.96-1.45 0.113 
Age 0.92 0.85-1 0.043 
LLIN at enrolment 0.74 0.54-1.01 0.057 
Hb at enrolment (g/dL) 0.9 0.84-0.97 0.007 
Village        
Albinama (ref) 1   		
Amahup 0.34 0.21-0.56 <0.001 
Balif 1.39 0.95-2.03 0.087 
Balanga 0.78 0.51-1.18 0.233 
Bolumita 2.22 1.52-3.23 <0.001 
Numangu 0.64 0.35-1.16 0.138 
Study Day      
Day 0-35 (ref) 1    
Day 36-80 1.81 1.28-2.57 0.001 
Day 81-175 1.01 0.71-1.44 0.945 
Day >175 0.58 0.4-0.85 0.005 
 
1IRRs were modeled per sampling interval using negative binomial generalized estimating equations allowing 
for repeated visits with log-link and an exchangeable correlation structure.  
2 molFOB in the follow-up interval (time-varying covariate).  
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Abstract  
 
BACKGROUND: The duration of natural P. falciparum infections is a fundamental parameter of the 
parasite’s infection dynamics. It is inherently difficult to study in endemic settings because of frequent 
super-infection and imperfect detectability of parasite clones. The effects of age or exposure to new 
infections on the duration of P. falciparum infections are poorly studied. In non-African settings, co-
infection with other Plasmodium species may further influence the dynamics of P. falciparum 
infections. 
 
METHODS: We estimated P. falciparum infection duration and the force of infection (FOI), i.e. the 
acquisition rate of new infections, using the triplet model that allows for imperfect detectability of 
clones. Samples were obtained from two treatment-to-reinfection cohorts in settings of different 
transmission intensity in Papua New Guinea (PNG). Both studies comprised initial clearance of blood-
stage parasites followed by six to eight months of two- to four-weekly blood sampling. P. falciparum 
clones were distinguished by msp2 genotyping.   
 
RESULTS: P. falciparum infection durations in PNG were generally short, and lasted 38 days 
(median, CI95: 34-42) in the high-transmission setting and 62 days (median, CI95: 42-127) in the 
intermediate-transmission setting. In both studies infection durations were longer in the higher 
exposed children. No pronounced trend in infection duration with age was observed. Clone 
detectability was higher in the high-transmission setting (median 78%, CI95: 72-82), despite the higher 
number of concurrent clones compared to the intermediate-transmission setting. Clone detectability at 
intermediate transmission varied with exposure and age and ranged between 49-73%. In the high-
transmission setting, the duration of individual infections almost matched the length of sampling 
intervals. Here, adjusting not only for clone detectability but also infection duration substantially 
increased the FOI estimate.  
 
CONCLUSIONS: P. falciparum infections in PNG children are shorter than those in similarly aged 
Ghanaian children. This may reflect evolutionary adaptation of the parasite to settings of differing 
seasonality, differences in Plasmodium species composition, or differences in parasite diversity 
encountered by the host’s immune system.    
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Introduction  
Asymptomatic, often chronic infections make up the majority of malaria infections and are considered 
the main reservoir sustaining malaria transmission (1), yet surprisingly few studies have investigated a 
fundamental parameter of infection dynamics: the duration of a distinct parasite infection in a host (2–
5).  The persistence of an individual infection can only be monitored by genotyping this parasite clone 
as frequent super-infections prohibit determining infection duration by microscopy or diagnostic PCR. 
Unlike P. vivax, P. falciparum has no dormant liver stage that could re-activate after clearance of a 
primary infection. Therefore prolonging the duration of an infection is a pivotal strategy to maximize 
transmission success for P. falciparum. To permit persistence in the host despite immunological 
recognition, P. falciparum switches the major parasite antigen displayed on the infected erythrocyte 
surface by mutually exclusive expression of highly diverse var-genes (6). The duration of an untreated 
P. falciparum infection in the human host thus depends on the host’s anti-malarial acquired immunity 
counterbalanced by the parasite’s ability to evade this immune response (7).  
Some of the most detailed data on the course and duration of P. falciparum infections derive from 
treatment of neurosyphilis patients after deliberate malaria infection in the pre-antibiotic era (8–10). 
Parasitemia lasted on average 211 days and rarely exceeded one year (8,10,11). However, the 
relevance of this data for natural P. falciparum infections in endemic settings is questionable, as hosts 
were usually malaria-naïve, received one highly controlled infection and were often treated with sub-
curative treatment doses. In contrast, people living in endemic countries are frequently super-infected, 
acquire semi-immunity to malaria with repeated exposure to diverse parasites (12) and only seek 
treatment following symptoms. Naturally clearing malaria infections are thus rarely detected in 
endemic settings and their dynamics are challenging to study.  
Differentiation of parasite clones by genotyping is required for studying individual malaria infections 
in endemic settings where super-infections are common. However, several factors can impede the 
detection of parasite clones in peripheral blood samples: (i), technical problems associated with 
genotyping PCR limit the capability to amplify minority clones (Messerli & Hofmann et al., 
submitted); (ii), biological features of P. falciparum sometimes prevent detection of a parasite clone, 
e.g. when sequestration of late-stage parasites in deep organs leads to periodical absence of 
synchronized clones from the peripheral circulation; (iii), fluctuating parasite densities may 
occasionally fall below the limit of detection of PCR; or (iv), the small volume sampled may simply 
not contain a parasite of the minority clone if parasite densities are low. Detectability of P. falciparum 
clones is hence imperfect especially in semi-immune individuals who are able to control parasite 
densities (13). In a longitudinal cohort in Northern Ghana detectability decreased from 60% in young 
children to less than 20% in individuals >60 years of age (4). The declining detectability mirrored the 
decrease of parasite densities with age (4,14). Adjusting for imperfect detectability using mathematical 
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models is thus crucial to obtain accurate estimates of acquisition or clearance rates of natural P. 
falciparum infections (3,4,15,16).  
The effect of natural acquired immunity on acquisition or clearance rates themselves is not well 
understood. In absence of a direct and individual measure of anti-malarial immunity, age is often 
utilized as surrogate marker. However, the study of age trends in infection duration requires intensive 
monitoring of asymptomatic carriers of all ages over extended periods of time, in combination with in-
depth molecular analysis of samples, and is thus rarely done. One suitable dataset exists, in which P. 
falciparum high-resolution genotyping was used in a cohort in Northern Ghana covering the whole age 
range (17). To study the effect of acquired immunity on P. falciparum infection duration, this data has 
been analyzed with more and more complex models (15,3,14,4). Using the “triplet” model approach, 
average infection duration over all ages was estimated at 168 days.  Age-trends in infection duration 
were non-monotonic with longest infections observed in children aged 5-9 years (216 days), 
suggesting that no simple linear relation of acquired immunity and P. falciparum infection duration 
exists (4).  
Data on the durations of non-African P. falciparum infections is scarce. Outside of Africa, P. 
falciparum often co-exists with other malaria species, which may interact and alter the course of an 
infection (18,19). The few studies assessing P. falciparum infection durations in Puerto Rico (20), 
West Papua (2) or Papua New Guinea (21) are based on blood-slide positivity, and only one dataset 
comprises molecular analysis of clonal infections with simple adjustment for imperfect detectability 
(22). 
Durations of natural infections are much needed parameters to inform models of malaria transmission. 
It is crucial to investigate this parameter in different endemic settings, and importantly in areas with 
different seasonal patterns. To fill this gap in knowledge, the dynamics of natural P. falciparum 
infections were investigated in two cohorts of children from Papua New Guinea (PNG), for which 
detailed clinical as well as molecular parasitological data was collected (23,24). Detectability-adjusted 
infection duration and clone acquisition rates (i.e. the force of infection, FOI) were determined using 
the triplet model. To explore the effect of frequent super-infection on P. falciparum infection 
durations, children were stratified by individual exposure to P. falciparum (25) (chapter 3). Individual 
exposure, besides age, can further serve as proxy for acquired immunity particularly in settings of 
heterogeneous transmission where age may not be a suitable surrogate marker (chapter 3). 
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Methods 
Field studies 
Samples derived from two cohort studies conducted in areas of medium to high perennial transmission 
along the North Coast of PNG (23,24). The study design was comparable in that both cohorts 
comprised an initial anti-malarial treatment and regular active as well as close passive follow-up. 
Details of treatment regimens and study design can be found elsewhere (23,24). Briefly, the first 
cohort comprised 206 children aged 5-14 years from Mugil area/Madang province who were treated 
with artesunate monotherapy in June 2004 and subsequently followed for 6 months. Finger-prick 
blood samples were collected in monthly intervals. The second cohort was performed in Maprik 
area/East Sepik province, and comprised 504 children aged 5-10 years who received either blood-stage 
or blood-plus-liver-stage radical cure in August to September 2009 and were followed for 8 months. 
Finger-prick blood samples were collected in 2-weekly intervals in the first three months of follow-up 
and monthly thereafter. The two cohorts are further referred to as the “Mugil” and “Maprik” cohorts. 
In both studies, finger-prick blood samples were collected from children that presented to the 
collaborating health centers or field team showing signs and symptoms of malaria. Scientific approval 
and ethical clearance was obtained from the PNG Medical Research Advisory Council, plus the Walter 
and Eliza Hall Institute and the Veteran’s Affairs Medical Center, Cleveland, Ohio, the PNG IMR 
Institutional Review Board and the ethics committee of Basel, Switzerland. 
 
Laboratory methods 
Blood slides of all samples were examined for P. falciparum parasites using light microscopy and 
molecular methods as described previously (23,24). For molecular detection DNA was extracted from 
all blood samples using the QIAamp 96 DNA Blood kit (Qiagen; Mugil cohort) or the FavorPrep™ 
96-well genomic DNA extraction kit (Favorgen; Maprik cohort). All samples were screened for the 
presence of P. falciparum using either PCR-ligase detection reaction fluorescent microsphere assay 
(PCR-LDR-FMA (26); Mugil cohort) or quantitative PCR (qPCR (27,28); Maprik cohort). In all 
samples positive for P. falciparum by any method, individual parasite clones were distinguished by 
amplifying the length-polymorphic merozoite surface protein 2 (msp2) marker in nested PCR followed 
by high-resolution capillary electrophoresis (29,30). Electropherograms were analyzed using 
GeneMapper® software v3.7 (Applied Biosystems). 
 
Estimating individual exposure 
Individual exposure was calculated for each child from the number of new P. falciparum clones 
detected during follow-up divided by the individual time at risk (25) (chapter 3). A new infection was 
defined as an msp2 allele not present in the two preceding genotyping-positive samples collected 
during active or passive surveillance without further allowing for imperfect detectability or clearance 
of clones (chapter 3). 
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Estimating clone detectability. infection duration and FOI  
In order to estimate clonal detectability and compute detectability-adjusted FOI and clearance rates, 
the “triplet model” approach was used (4) (details presented in Supplement S1 Text).  Briefly, 
presence and absence of each allele per child was recorded as a string of “1” (genotype present), “0” 
(genotype not present) or “?” (sample missing). To preserve the time intervals of sampling, data from 
unscheduled samples collected during passive case detection were merged to the closest active follow-
up visit. A sliding window of three consecutive samples was passed along the string of 1’s , 0’s and 
?’s, so that each sample could appear at any position in a triplet. Triplet patterns starting with a 
positive detection were counted. Estimates of detectability “S” and detectability-adjusted clearance 
rate per timestep ”M” were computed using a Bayesian Markov chain Monte Carlo (MCMC) 
algorithm in WinBugs/JAGS software, assuming a Markov process for clearance and assuming the 
probability of re-infection with the same genotype within the same interval to be close to zero. Raw 
allele-specific incidence rates were calculated by dividing the number of gains (pattern “01”, i.e. 
negative at t1 and positive at t2) by the number at risk for infection at time t0 (patterns “00” and “01“), 
adjusted for M and S, and summed over alleles to obtain an detectability-adjusted incidence per time 
step “Λ“. Lastly, M and Λ were transformed from transition probabilities to a continuous-time 
clearance rate “µ” and continuous-time aquisition rate “λ”, i.e. FOI, with respect to the sampling 
interval used in the specific studies. In the Maprik cohort, sampling intervals differed between the first 
three months (2-weekly) and later five months (4-weekly) of the study, and thus an averaged interval 
timestep of 19.4 days was used.  
To ensure that parameters reflected natural infections and were not biased by anti-malarial treatment, 
we excluded triplets that comprised an anti-malarial treatment. In a pilot sensitivity analysis, this 
strategy was compared to the full dataset and a restricted dataset excluding all triplets from children 
that received anti-malarial treatment. Estimates of detectability and infection duration were 
comparable using both exclusion strategies (Supplement S2 Table). Estimates of infection duration 
using the restricted datasets were longer than estimates obtained using the full dataset (Supplement S2 
Table). Since the first strategy (excluding only those triplets that comprised treatment) allowed 
retaining more datapoints, this strategy was used for all further analyses. 
 
 
Results 
Comparing P. falciparum transmission between cohorts   
P. falciparum transmission was higher in the Mugil cohort, performed 2004, than in the Maprik 
cohort, performed five years later. P. falciparum PCR prevalence at baseline, i.e. before the initial 
treatment, was 67% in Mugil and 24% in Maprik (Table 1). P. falciparum was the most common 
infection in Mugil but not in Maprik, where P. vivax was twice as prevalent (48%, Table 1). After the  
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respective initial anti-malarial treatment regimen (23,24), re-infection with P. falciparum occurred 
faster in the Mugil cohort (median time-to-reinfection: 55 days (23)) than in the Maprik cohort 
(median time to re-infection: >225 days (24)). In Mugil all but 31 (15%) of 206 children were re-
infected during follow-up, as opposed to Maprik where more than two thirds of children (346/504) 
were not re-infected until the end of the study.  
P. falciparum density by LM was 100-fold lower in Mugil versus Maprik (Table 1). In contrast, 
multiplicity of infection (MOI), i.e. the numbers of concurrent clones per sample, as well as the 
incidence of new clones in the blood were higher in Mugil than in Maprik (Table 1).  
 
Table 1. Comparison of Plasmodium parasitological parameters between cohorts. 
 
Mugil cohort 
n=206 
(CI95) 
Maprik cohort 
n=504 
(CI95) 
p-value1 
Enrolment parameters    
P. falciparum PCR prevalence (%) 67 (61-74)  24 (20-28) < 0.001 
P. vivax PCR prevalence (%) 34 (28-41) 48 (43-52) 0.001 
Parameters assessed during followup    
P. falciparum GMPD2 by LM  12 (10-14)  1418 (1043-1928)  <0.001 
Mean P. falciparum MOI3 (clones/sample) 1.6 (1.6-1.7)  1.3 (1.3-1.4)  <0.001 
Proportion of single-clone infections (%) 57 (54-60) 76 (72-80) <0.001 
Mean exposure (number of new clones/year4) 6.4 (5.8-7.0) 4.1 (3.6-4.6) <0.001 
1 p-values were calculated using Chi2 test for differences in prevalence or proportions, and using Mann-
Whitney -U test for differences in means.  
2 GMPD: geometric mean parasite density 
3 MOI, multiplicity of infection. Only P. falciparum-positive samples were included in calculation of the mean. 
4 Individual exposure calculated as the number of new clones/year observed in the blood stream (see methods). 
Mean was calculated including only children that were re-infected.  
 
 
Triplet counts per study 
Due to the higher number of P. falciparum infections in Mugil compared to Maprik, three times more 
triplets starting with a positive detection were counted in Mugil (Table 2). In addition, intermittent 
missed follow-visits were much more frequent in Maprik and 34% of triplets in the Maprik cohort 
included a missing sample (Table 2), leading to higher uncertainty of estimates obtained for this 
cohort.   
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Table 2. Triplet counts1 by study. 
 Mugil cohort Maprik cohort 
Triplet Counts % of triplets Counts % of triplets 
+ + X2 525 44.7 91 31.9 
+ – + 61 5.2 22 7.7 
+ – – 462 39.4 75 26.3 
+ – ? 78 6.6 28 9.8 
+ ? + 14 1.2 20 7.0 
+ ? – 34 2.9 49 17.2 
Total 1174 100 285 100 
1 Only triplets starting with a positive detection were counted. 
2 X: any of +, –, or ? 
 
 
Detectability of P. falciparum clones 
Overall, clone detectability was 78% (CI95: 72-82) in Mugil and only 57% (CI95: 43-70) in Maprik 
(Table 3). The effects of age and exposure, as surrogate markers of immunity, on clone detectability 
were investigated by forming age groups and groups of low and high exposure to P. falciparum within 
the two studies (Table 4). Age and exposure were not correlated in either study (Supplement S3 
Figure, Gaussian generalized linear regression p > 0.05). 
 
Table 3. Triplet model estimates by study. 
Parameter Unit 
Mugil cohort 
Median (CI95) 
Maprik cohort 
Median (CI95) 
Detectability S %  78  (72-82)  57  (43-70) 
Adjusted acquisition rate λ infections/year  14.4  (13.2-15.9)  3.3  (2.7-4.2) 
Infection duration µ-1 Days  38  (34-42)  62  (42-127) 
 
 
In Maprik, where transmission was intermediate, clone detectability was lower in high-exposed 
children (50%, CI95: 37-66) compared to low-exposed children (73%, CI95: 49-90, Figure 1A). Clone 
detectability was slightly higher in older than in younger children in Maprik (49%, CI95: 32-71; versus 
61%, CI95: 44-76, Figure 1A). Detectability declined with decreasing proportion of single-clone 
infections and with increasing MOI (Figure 1B&C). Clone detectability in Maprik was therefore lower 
the more concurrent clones were present.  
In contrast, in the high-transmission setting of Mugil, detectability was equal in all subgroups despite 
variations in MOI and the proportion of single-clone infections (Figure 2A-C). In both studies, 
differences in parasite density between age and exposure groups were not pronounced, although in 
some cases significant (Figures 1D, 2D).  
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Figure 1. P. falciparum clone detectability and molecular parameters of infection by age 
or exposure group in the Maprik cohort. (A) Median detectability with 95% CI. (B) MOI by 
msp2 genotyping; mean MOI is shown as black diamond. (C) Proportion of single clone 
infections among P. falciparum-positive samples by msp2 genotyping. (D) Parasite density by 
LM. p-values were calculated using Mann-Whitney-U test (B, D) and Chi2 test (C). 
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Figure2.  P. falciparum clone detectability and molecular parameters of infection by age or 
exposure group in the Mugil cohort. (A) Median detectability with 95% CI. (B) MOI by msp2 
genotyping; mean MOI is shown as black diamond. (C) Proportion of single clone infections 
among P. falciparum-positive samples by msp2 genotyping. (D) Parasite density by LM. p-
values were calculated using Mann-Whitney-U test (B, D) and Chi2 test (C).  
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Table 4. Characteristics of age groups and groups of low and high exposure by study.  
 
Mean  
(±StDev) 
Number 
of children 
Number  
of triplets1 
Mugil cohort2    
Young 7.9  (±0.9) years 91 479 
Old 10.5 (±1.2) years 115 695 
Low-exposed 3.4 (±1.1) new clones/year 903 363 
High-exposed 9.6 (±3.2) new clones/year 853 749 
Maprik cohort2    
Young 6.2 (±0.7) years 245 127 
Old 8.9 (±0.9) years 259 158 
Low-exposed 2.2 (±0.7) new clones/year 1013 88 
High-exposed 7.6 (±3.0) new clones/year 573 190 
1 Only triplets starting with a positive detection were counted. 
2 Median age and median exposure per study were used as cutoff value to form groups of equal size. 
3 Children remaining uninfected throughout follow-up were not included in the exposure categories. 
 
 
Duration of infection 
In Mugil (high transmission), infections persisted on average only 38 days (CI95: 34-42, Table 3). In 
Maprik (intermediate transmission), infections were slightly longer and lasted on average 62 days 
(CI95: 42-127). The difference between studies was mainly due to long infection durations in highly 
exposed children in Maprik (98 days, CI95: 51-713; Figure 3A), while infections in the low-exposed 
children in Maprik were as short as in children from Mugil (37 days, CI95: 25-68). A longer duration 
of infection in higher exposed children was also observed in Mugil, but the difference was less 
pronounced compared to Maprik (low-exposed, 32 days, CI95: 27-39; high-exposed, 42 days, CI95: 37-
49, Figure 3B). No pronounced trend in the duration of infection was observed between age groups 
(Figure 3). 
 
Estimating FOI 
Modeling the FOI, i.e. the acquisition rate of new infections, by adjusting for clone detectability and 
infection duration revealed a much larger difference in transmission between the two cohorts than 
anticipated based on means of individual exposure (Table 2, Table 3). Median modeled FOI was 14.4 
infections/year (CI95: 13.2-15.9) in Mugil compared to 3.3 infections/year in Maprik (CI95: 2.7-4.2).   
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Figure 3. P. falciparum infection duration in the Maprik (A) and Mugil  
(B) cohorts. Median infection duration in days is shown by age group (left 
panel) and in low- versus high-exposed children (right panel). Error bars 
represent 95% CIs.  
 
 
Discussion  
This study contributed novel insights into the dynamic of non-African natural P. falciparum 
infections. In two cohort studies performed in PNG in settings of different transmission intensity, P. 
falciparum infection durations were significantly shorter than durations estimated using the same 
methodology in a previous cohort study in Ghana (31). Averaged over all ages, infections in the 
Ghanaian cohort lasted 168 days and even 216 days in 5-9 year-old children. In that cohort, sampling 
was performed in two-monthly intervals and clone detectability was much lower (40% in 5-9 year old 
children). Such large differences in the infection duration may reflect biological differences between 
African and PNG parasite populations, which face different environmental challenges. In Ghana, the 
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6-months long dry season is characterized by a virtually complete absence of rain (31), whereas 
seasonality is less pronounced in PNG and intermittent rainfall is frequent even in the dry season (32). 
While persistent chronic infections are thus required to re-initiate transmission after the dry season in 
many African settings (33), malaria transmission is perennial in PNG with seasonal fluctuations (32) 
and hence the selective pressure on the parasite population to maintain long-lasting chronic infections 
may be lower in PNG. 
In addition, co-infection with other Plasmodium species, mainly with P. vivax, occurs frequently in 
PNG but less so in Africa and may have an impact on the duration of P. falciparum infections. While 
parasite density and the risk for malaria episodes are altered in mixed P. falciparum/P. vivax infections 
(chapter 3), we found no clear indication that differences in P. vivax carriage influenced P. falciparum 
infection durations (Supplement S4 Text). In Mugil, none of the assessed parameters of P. falciparum 
infection dynamics varied with P. vivax carriage (Supplement S4 Text). In Maprik, P. vivax carriage 
and exposure to P. falciparum were correlated, which prohibited investigating the effect of P. vivax 
carriage alone on infection duration (Supplement S4 Text).  
Lastly, differences in parasite diversity between P. falciparum populations from Africa and PNG may 
contribute to the observed differences in infection duration. Recent analyses found a lower P. 
falciparum var-gene diversity in PNG compared to African populations (34,35), contrary to an earlier 
study describing equal var-gene repertoires (36).  The ability of the parasite to switch to a var-gene 
variant previously not encountered by the host’s immune system may hence be reduced in PNG 
compared to Africa, leading to earlier clearance.  
The effect of acquired immunity on the duration of malaria infections is poorly understood, partly 
because a direct measure of protection is lacking. Age is widely used as surrogate marker (12) 
although a composite measure of age and exposure would more accurately reflect cumulative past 
exposure of an individual and hence immunity. No pronounced difference in infection duration was 
observed between age groups in the two PNG cohorts. Although the age range covered in both cohorts 
may be too small to detect significant age patterns, previous analyses demonstrated lower risk of P. 
falciparum episodes and high-density infections (23) as well as higher prevalence and titers of 
protective antibodies in children older than 9 years in the Mugil cohort (37–39). These data indicate 
that significant differences in immunity exist between the two age groups in the Mugil cohort. 
However, these differences did not have an impact on the duration of P. falciparum infections.   
Longer infection duration observed in high-exposed compared to low-exposed children within both 
studies is therefore probably attributable to the interaction of concurrent clones and frequent super-
infection, rather than differences in anti-malarial immunity. In contrast, an overall shorter infection 
duration was observed in Mugil (high transmission) compared to Maprik (intermediate transmission). 
This suggests that differences in immunity may play a role when drawing comparisons between 
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studies, where differences in immunity are supposedly larger than within a cohort. It is conceivable 
that children from Mugil, probably characterized by more advanced immunity owing to higher 
transmission, are better equipped to control several concurrent clones than children from Maprik, 
leading to shorter infection durations despite higher transmission.    
In the Ghanaian cohort, clone detectability as well as parasite densities decreased with age (31). In 
PNG, detectability was not strongly related to overall parasite density but rather inversely correlated to 
MOI. This effect was stronger in intermediate-transmission Maprik than in high-transmission Mugil. 
One possible explanation may be a more advanced anti-malarial immunity of children in the Mugil 
cohort, who were almost constantly infected. As result they might be better able to control the density 
of superinfecting clones and to prevent expansion of a dominant clone in an already populated host, 
which is supported by the overall lower parasite densities (Figure 2D). Anti-malarial immunity in 
children from Maprik, in contrast, may still be incomplete and permit high density clones that could 
suppress minority clones. Concurrent clones may thus be more in numerical equilibrium and therefore 
easier detectable in children of the Mugil cohort compared to children from Maprik, despite the overall 
lower densities and higher MOI in Mugil.   
When FOI was modeled including adjustments for clone detectability and clearance rate, it became 
evident that accurately estimating FOI is complex when sampling intervals approach the duration of 
infection. Median infection duration in Mugil was only 38 days and sampling was performed in 
monthly intervals. This suggests that a large proportion of infections in Mugil were only present in the 
host at one sampling visit, where they may or may not be detected. In contrast, sampling in Maprik 
was performed in two-weekly to monthly intervals and infections lasted on average 62 days. Infections 
were thus present in the host at up to four sampling visits in Maprik and were more likely to be 
detected compared to the Mugil cohort. As result, modeled FOI differed more drastically between 
studies than was anticipated based on the mean individual exposure, which does not take into account 
infection duration.   
Because the primary objective of this analysis was assessing the duration of natural infections, we 
excluded triplets that included anti-malarial treatment when a child was symptomatic. Since malaria 
episodes are often caused by a new infection (40), we thereby selectively removed samples with a 
recent new P. falciparum infection. As result, the true FOI is likely even higher than the modeled FOI 
in both studies. Because more malaria episodes occurred in the Mugil compared to the Maprik cohort 
(23,24), this bias is expected to be more pronounced in Mugil. The true differences in exposure to new 
infections between the two studies may thus have been even larger than described by the modeled 
FOI.  
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SUPPLEMENT 
 
Supplement S1 Text:  
Estimation of force of infection and clearance rates allowing for imperfect detectability 
 
Analysis of the genotypes of malaria parasites in sequential blood samples collected several weeks 
apart from the same infected host, can be used to estimate the force of infection (FOI) of the parasite. 
Such data can also be used to estimate how long parasites persist if they are not treated. A significant 
complication is that even PCR does not detect all infections (1). This means that, when serial samples 
from the same host are considered, disappearance of a specific genotype in the second sample of a pair 
(a “loss” corresponding to a (+ −) pattern) can be either the result of imperfect detection of a persisting 
clone, or of clearance. Similarly, a “gain” (− +) can be the result of acquisition of parasites of the 
specific genotype, or of imperfect detection in the first sample of the pair.  
The mathematics is best illustrated by the case of exchangeable genotypes, i.e. the rates of clearance of 
each genotype are the same and each genotype is equally detectible. In applications where this 
assumption does not hold, analyses can be carried out stratified by genotype or host characteristics. To 
estimate the rates of clearance allowing for the proportion of clones that are detected, sequences of at 
least three samples need to be considered. The following text is an expanded version of the original 
exposition of this method (2). 
Clearance and detectability 
To estimate the clearance rates and the detectability, a simple analytical approach is to group the data 
into “triplets” comprising sequences of three samples starting with each one that typed positive for 
each specific genotype, so that the total number of triplets is equal to the sum over all genotypes of the 
positive typings. These are then categorized according to the typing result and the presence of data for 
the second and third samples into categories (Figure 1 and Table 1). 
The analysis estimates both the detectability and the probability that an infection existing at the start is 
cleared during the interval between the first sample (t=1) and the second sample (t=2) assuming a 
Markov process for clearance (2), and assuming the probability of reinfection within the same interval 
to be close to zero. The typing results at t=2 depend on probability, (M) , of clearance of an infection 
during any single interval and on the proportion of true infections detected in any given sample (S), as 
indicated in Table 1. In the case that the sample at t=2 is negative, the samples at t=3 are informative 
about whether a negative sample at t=2 was a true, or false negative. This method classifies pairs or 
triplets commencing with a positive sample into four categories (numbered 1-4 in Table 1 and Figure 
Chapter 4: Dynamics of natural P. falciparum infections in PNG  
 
104 
Working manuscript 
1A), depending on the existence of data from samples at time t=2 and t=3. The likelihood of each of 
these 4 patterns, equivalent to the probability that it will be observed, conditional on the availability of 
the required typing data, is given in Table 1.  
The original method (2) (Figure 1) analyses only the minimal dataset required to make the problem 
identifiable, counting only the pairs or triplets where samples are available at t=2, and distinguishing 
between cases where only pairs of samples (t=1 and t=2) are available from those where full triplets 
are available (t=1, t=2 and t=3). When the second sample is positive, the status at t=3 is not 
considered. The approach can be extended to incorporate information from all triplets with data from 
t=3, or from more complicated sample sets, including sequences of 4 or more samples and sequences 
with missing data. One such example is the case when the data at t=2 is missing (Figure S1B), but a 
sample at t=3 has been typed. Positivity at t=3 is then also indicative of persistence, and thus the t=3 
provides some additional information about M and S. In the case that complete data are available from 
longer sample sets, the method is equivalent to that of Sama (3). The challenge of extending the 
methodology to analysis of longer series with complex patterns of missing data remains to be 
addressed.  
Table 1. Patterns of infection detected by genotyping in sequences starting with positive samples, 
and their likelihoods 
K First sample Second sample Third sample Likelihood 
1 + + -, +, or missing !" = 1 − & ' 
2 + - + !( = 1 − & ( 1 − ' ' 
3 + - - !) = 1 −	!( − !" 
4 + - Missing !+ = 1 −	!" 
5 + Missing + !, = 1 − & (' 
6 + Missing - !- = 1 −	!, 
 
The values of M and S can be estimated by maximum likelihood from the overall likelihood 
constructed by multiplying the likelihoods for all the observed triplets, or equivalently from the log 
likelihood:  
./! = /0./!0+01"  
 
where /0 is the frequency of triplet pattern k (Table 1). Alternatively, a Bayesian Markov chain Monte 
Carlo (MCMC) algorithm can be employed using WinBugs or JAGS software assigning uniform 
priors to both M and S (see Appendix below). The decision points in Figure 1 then correspond to 
stochastic nodes with the probabilities for each branch proportional to the likelihoods from Table 1. 
The MCMC approach has the advantage of providing interval estimates for the parameters, and also 
allows the uncertainty in the estimation of M and S to be propagated in further calculations (e.g. bias-
adjustments in estimates of FOI, see below). 
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Figure 1. Classification of triplets, illustrated as branching process. The circles represent 
stochastic notes, the squares represent branching where the frequencies depend on whether samples 
are available, and thus do not provide information about infection dynamics. (A) Analysis including 
only pairs and triplets with data at t=2. (B) Analysis including triplets with missing data at t=2.  
 
Infection/Acquisition probability 
The acquisition probability for each genotype is estimated from the data of sequential pairs of samples, 
where the sequence starts with a sample that typed negative. The naïve estimate of the average number 
of infections acquired in each interval for genotype, i, is then: 
Λ′4 = /5	6/5	5 	+ 	/5	6 	
where /5	6 is the total number of “gains” (− +) divided by the total intervals at risk, which is 
computed from sum of the number of “gains”, /5	6 , and /5	5 , the number of (− −) pairs for the 
genotype. This is a biased estimate of the true probability that there is a new infection during the 
interval,  Λ4, because of imperfect detection, which might affect either the first or second sample of the 
pair. The bias depends on M, S, and also on 84, the true point prevalence of the genotype (i.e. the 
proportion of hosts infected by it on average at a single time point) (Table 2).  
 
Table 2. Patterns of infections in sequences starting with samples testing negative for a specific 
genotype (i), and their probabilities of occurrence. 
 
K 
True 
pattern 
(T) 
Probability that 
this pattern 
occurs 
Probability that 
the first sample 
tests negative 
Probability that 
this pattern occurs 
and the first 
sample tests 
negative (Pr(T)) 
Probability (− −) 
is observed  
Pr(− − ¦T=k) if 
the first sample 
tests negative 
Probability (− +) 
is observed  
Pr(− +¦T=k) if 
the first sample 
tests negative 
1 - (1 – pi)(1 – Λi) 1 (1 – pi)(1 – Λi) 1 0 
2 + (1 – pi)Λi 1 (1 – pi)Λi 1 – S S 
3 + - piM 1 – S piM(1 – S) 1 0 
4 + + pi (1 – M ) 1 – S pi (1 – M ) (1 – S) 1 – S S 
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The overall probability that the observed pattern for genotype i in any sequential pair of samples is     
(− −) is obtained as: 9: −	− = 9: T 9: −	− ¦T = k  
i.e. 9: −	− = 1 − 84 1 − Λ4 + 1 − ' 1 − 84 >4 + 1 − ' 84& + 84 1 − & 1 − ' (, 
 
and the overall probability that the observed pattern is (- +) is: 9: −	+ = 9: T 9: −	+ ¦T = k  
i.e.	 9: − 	+ = ' 1 − 84 >4 + 84 1 − & (1 − ')'. 
 
In the large sample case, the observed proportion of intervals during which an infection appears to be 
acquired is then the ratio: Λ′4 = 9: −	+9: −	− + 9: −	+ 	
which is therefore equivalent to: 
 Λ′4 = '>4 − '84 >4 − 1 − ' 1 − &1 − '84  
and,	 Λ′4 = '>4 − 8′4 >4 − 1 − ' 1 − &1 − 8′4 	
 
where:	8′4 = '84, is the point prediction of the observed prevalence which is estimated by: 8′4 = /6/5 	+ 	/6 /5 is the total number of samples testing negative for the genotype, and /6 is the total testing positive.  
Solving for Λ4 and substituting the field-based estimates, provides a formula for the bias adjusted 
estimate of Λ4 as a function of 8′4 and of the estimated detectability, ', and clearance probability, & .  
 
>4 = ΛA4 − 8′4 ΛA4 + 1 − ' 1 − &' − 8′4  
 
This is a correction to the formula originally published in 1999 (2). 
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The ratio, >4 ΛA4 which measures the bias in the crude estimate of the number of new infections, is 
highly sensitive to '. If detection is perfect, it has a value of 1.0, corresponding to no bias. At low 
values of ', >4 can be substantially higher than ΛA4	especially if & is high, corresponding to long 
survey intervals or rapid turnover of infections (Figure 2).  Within the ranges observed in field studies 
in Tanzania and Ghana (2,3) the ratio of >4 ΛA4 is a non-monotonic function of ' but remains fairly 
close to unity (implying only modest levels of bias). The bias is very insensitive to 8′4 over a wide 
range of prevalence values. In general, since the analysis is applied to genotype specific data, 8′4 is 
expected to be low. 
 
 
                                   & = 0.5 
  
                 
   >4 ΛA4        
& = 0.2 
                     & = 0.1  
                     & = 0.05  
 
 
 
Figure 2. Bias in estimated FOI. The quantity plotted is the ratio of the true value to the unadjusted 
estimate in each case for 8′4 = 0.002	. The horizontal dashed line corresponds to the case of no bias.  
 
 
Conversion to rates & and >4 are estimates of transition probabilities, and are therefore specific for the interval length used 
in any specific study. These must be converted to rates in continuous time if they are to be compared 
across studies with different interval durations. The continuous time analogues correspond to the 
reversible catalytic model (4,5). This provides expressions for transition probabilities as functions of 
the rates:   >4 = F4F4 + GH 1 − IJ8 − F4 + GH K 	
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and: 	& = GHF4 + GH 1 − IJ8 − F4 + GH K 	
 
where t is the duration of the inter-survey interval, G is the estimate of the clearance rate, and F4 is the 
estimate of the genotype specific FOI. Rearrangement of these formulae and solving for GH and F4 
gives: 
GH = −&./ 1 − >4 + &>4 + & K	  
 
and:  F4 = >4& GH 
 
The overall FOI is estimated as the sum of the individual F4	values. Although we use a common value 
of & across all genotypes, this analysis leads to slightly different values of GH. The mean of these 
calculated allele-specific values is reported as the clearance rate, G. The reported average duration of 
infection in days is then proportional to the reciprocal of this value, 1/G.  
 
Interval estimation  
Estimation of FOI, clearance rates, and detectability can be carried out by Maximum Likelihood, or 
alternatively by Bayesian MCMC. The latter has the advantage that it provides sampling-based 
interval estimates for all the parameters, potentially allowing for the uncertainties at each stage of the 
algorithm. Code for MCMC estimation is appended.  
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WinBugs/JAGS code for estimating &, S, F4, GH. 
 
# IMPLEMENTATION OF THE MODEL OF FIGURE S1A WITH DETERMINISTIC 
ESTIMATION OF THE FORCE OF INFECTION 
model {   
#ESTIMATION OF M AND S 
  L1<- (1-M)*S 
  L2<- (1-M)*(1-M)*(1-S)*S  
  L3<- 1 - L1- L2 
  L4<- 1 - L1 
 
#   
  pr2<- L2/(L2+L3) 
  s1total <- n11+n101+n100+n10 
  s2total <- n101+n100 
 
# binomial sampling of stochastic nodes 1, 2 
  n11  ~ dbin(L1,s1total) 
  n101 ~ dbin(pr2,s2total) 
 
# uniform prior for M and S  
  M ~ dunif(0,1)  
  S ~ dunif(0,1)  
 
#ESTIMATION OF FORCE OF INFECTION AND BIAS ADJUSTMENT  
 for (i in 1:NumberOfGenotypes) 
   { 
   L[i] <- (lambdaPrime[i] - p[i]*(lambdaPrime[i] + (1-M)*(1-S)))/(S - 
p[i]) 
   p[i] <- n1[i]/n[i]  
   lambdaPrime[i] <- n01[i]/n0[i] 
 
# transform to continuous time 
   muDaily[i]<- -M*log(1-(L[i]+ M))/((L[i]+M)*t) 
   lambdaDaily[i]<- -L[i]*log(1 - (L[i]+M))/((L[i]+M)*t) 
 } 
 
#summaries over all genotypes 
ClearanceDaily<-mean(muDaily[]) 
FOIDaily<-sum(lambdaDaily[]) 
} 
 
 
# TEST DATA 
 
list(NumberOfGenotypes=7, n11=211, n101=61, n100=209,n10=71,t=14) 
 
n0[]  n01[] n[] n1[] 
560 11 3000 53 
560 18 3000 57 
560 10 3000 43 
560 9 3000 23 
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560 11 3000 56 
560 15 3000 72 
560 5 3000 15 
END 
 
# EXAMPLE INITIAL VALUES (1 CHAIN) 
list( 
M = 0.1440881879701678, 
S = 0.4112187770372916, 
logitlambdaPrime = c( 
-4.207892579282936,-4.168605593430168,-3.965568672495186,-
4.388163834738868,-3.892549139358283, 
-3.908037902822194,-5.066532048318275), 
logitlambdaPrimebar = -3.823480945836294, 
logitp = c( 
-4.086307570550217,-4.004132629521775,-4.390522771059175,-
4.994397880509394,-3.750283683731104, 
-3.892052972624451,-5.191441694450187), 
logitpbar = -4.172449215059147, 
tau = 2.818547930754359, 
taup = 2.08985431148514) 
 
# IMPLEMENTATION OF THE MODEL OF FIGURE S1B WITH STOCHASTIC ESTIMATION OF 
THE FORCE OF INFECTION 
model {   
#ESTIMATION OF M AND S 
  L1<- (1-M)*S 
  L2<- (1-M)*(1-M)*(1-S)*S  
  L3<- 1 - L1- L2 
  L4<- 1 - L1 
  L5<- (1-M)*(1-M)*S 
  L6<- 1 - L5 
#   
  pr2<- L2/(L2+L3) 
  pr3<- L5/(L5+L6) 
  s1total <- n11+n101+n100+n10 
  s2total <- n101+n100 
  s3total <- n1_1+n1_0 
 
# binomial sampling of stochastic nodes 1, 2 and 3 
  n11  ~ dbin(L1,s1total) 
  n101 ~ dbin(pr2,s2total) 
  n1_1 ~ dbin(pr3,s3total) 
 
# uniform prior for M and S  
  M ~ dunif(0,1)  
  S ~ dunif(0,1)  
 
#ESTIMATION OF FORCE OF INFECTION AND BIAS ADJUSTMENT  
 for (i in 1:NumberOfGenotypes) 
   { 
   L[i]<- (lambdaPrime[i] - p[i]*(lambdaPrime[i] + (1-M)*(1-S)))/(S - p[i]) 
   n1[i]~dbin(p[i],n[i])  
   n01[i]~dbin(lambdaPrime[i],n0[i])  
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# random effects for genotype specific prevalence and incidence 
   lambdaPrime[i]<- 1/(1+exp(-logitlambdaPrime[i])) 
   logitlambdaPrime[i]~dnorm(logitlambdaPrimebar,tau) 
   p[i]<- 1/(1+exp(-logitp[i])) 
   logitp[i]~dnorm(logitpbar,taup) 
 
# transform to continuous time 
   muDaily[i]<- -M*log(1-(L[i]+ M))/((L[i]+M)*t) 
   lambdaDaily[i]<- -L[i]*log(1 - (L[i]+M))/((L[i]+M)*t) 
 } 
 
#priors for metaparameters of random effects 
logitlambdaPrimebar~dnorm(0,1.0E-2) 
tau~dunif(0,10) 
logitpbar~dnorm(0,1.0E-2) 
taup~dunif(0,10) 
 
#summaries over all genotypes 
ClearanceDaily<-mean(muDaily[]) 
FOIDaily<-sum(lambdaDaily[]) 
} 
 
 
# TEST DATA 
 
list(NumberOfGenotypes=7, n11=211, n101=61, 
n100=209,n10=71,n1_0=30,n1_1=10,t=14) 
 
n0[]  n01[] n[] n1[] 
560 11 3000 53 
560 18 3000 57 
560 10 3000 43 
560 9 3000 23 
560 11 3000 56 
560 15 3000 72 
560 5 3000 15 
END 
 
# EXAMPLE INITIAL VALUES (1 CHAIN) 
 
list( 
M = 0.2938271930359447, 
S = 0.5093814682038473, 
logitlambdaPrime = c( 
-3.562748062328747,-3.678312884623953,-3.841609547868719,-
4.561559522968858,-3.54204822963872, 
-3.543603660614651,-4.123941440039693), 
logitlambdaPrimebar = -3.637727825838637, 
logitp = c( 
-4.164460955662759,-4.017057261011612,-4.191668882209104,-
4.558031283327824,-3.778424732596439, 
-3.785125363187561,-4.934854572547822), 
logitpbar = -4.653282454126015, 
Chapter 4: Dynamics of natural P. falciparum infections in PNG  
 
112 
Working manuscript 
tau = 2.097024953285597, 
taup = 2.599193884837493) 
 
 
# M,S, ClearanceDaily and FOIDaily are the main parameters of interest. 
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Supplement S2 Table: 
 
Table S2. Comparison of strategies to account for anti-malarial treatment in the Maprik cohort.  
 Full dataset 
Strategy 1 
Exclusion of children 
that received anti-
malarial treatment 
Strategy 2 
Exclusion of triplets 
that comprised anti-
malarial treatment 
Number of children 504 374 504 
Number of triplets1    
Total 351 230 285 
+ + X2 100 79 91 
+ – + 23 18 22 
+ – – 120 53 75 
+ – ? 36 26 28 
+ ? + 20 17 20 
+ ? – 52 37 49 
 Median (CI95) Median (CI95) Median (CI95) 
Detectability S 55 (41-68) 58 (44-72) 57 (43-70) 
Adjusted acquisition rate λ 
(infections/year) 3.8 (3.1-4.8)  2.8 (2.2-3.6)
3 3.3 (2.7-4.2)3 
Infection duration µ-1 (days) 47 (35-80) 69 (45-176) 62 (42-127) 
 
1 Only triplets starting with a positive detection are counted. 
2 X: any of +, –, or ? 
3 Exclusion of children that received anti-malarial treatment, or exclusion of triplets that comprised anti-malarial 
treatment introduces bias towards lower acquisition rates since highly exposed children, or time points of new 
infections, are selectively removed. Lower acquisition rates compared to the full dataset are therefore to be 
expected. 
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Supplement S3 Figure: 
 
S3 Figure: Age and exposure are not correlated in the Mugil and Maprik cohorts. 
Gaussian generalized linear regression revealed no significant associations between age and 
exposure (Mugil p=0.376; Maprik p=0.452)  
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Supplement S4 Text: 
 
 
Investigating the effect of P. vivax co-infection on P. falciparum infection duration 
 
 
. 
 
Figure 1. P. vivax co-infection and exposure to P. falciparum are highly correlated in the Maprik 
cohort but not the Mugil cohort. Exposure to P. falciparum is plotted against P. vivax carriage per 
child. Individual exposure to P. falciparum was calculated as described in the methods section (y-
axis). P. vivax carriage was calculated as the proportion of P. vivax qPCR-positive samples in all 
samples collected per child (x-axis). The median P. vivax carriage per study was used to define the 
cutoff between groups of low and high P. vivax carriage. Association of P. vivax carriage and exposure 
to P. falciparum was assessed using Gaussian generalized linear models. A significant association was 
found for the Maprik cohort (β = 5.95 [CI95: 4.59 - 7.31], p<0.001), but not the Mugil cohort (β = -0.81 
[CI95: -4.05 - 2.42], p=0.622). 
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Table 1. The apparent effect of P. vivax carriage on P. falciparum infection durations in the 
Maprik cohort is likely an artifact caused by the correlation of P. vivax carriage with exposure 
to P. falciparum. Differing P. vivax carriage has no effect on P. falciparum infection durations in the 
Mugil cohort. In the Maprik cohort, patterns in triplet model outcomes between groups of low and 
high P. vivax carriage match those between P. falciparum exposure categories. The median P. vivax 
carriage per study was used to define the cutoff between groups of low and high P. vivax carriage. 
 
 
Detectability S 
(%) 
Median (CI95) 
Infection duration µ-1 
(days) 
Median (CI95) 
Adjusted acquisition 
rate (λ) 
Median (CI95) 
Mugil cohort    
P. vivax carriage    
Low  79 (72-85) 41 (36-48) 14.7 (13.2-16.7) 
High  76 (67-83) 34 (29-41) 14.2 (12.4-16,6) 
P. falciparum exposure    
Low  79 (72-85) 32 (27-39) 9.6 (8.2-11.5) 
High 76 (67-83) 42 (37-49) 22.5 (20.2-25.3) 
Maprik cohort    
P. vivax carriage    
Low  63 (44-80) 48 (32-103) 1.8 (1.4-2.6) 
High 51 (36-69) 88 (46-660) 10.6 (7.9-14.1) 
P. falciparum exposure    
Low  73 (49-90) 37 (25-68) 4.1 (3.1-6.1) 
High 50 (37-66) 98 (51-713) 28.9 (21.6-38.8) 
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SUPPLEMENT 
S1 TEXT 
 
Evaluation of the multivariate analysis (GEE models) of P. vivax  and P. falciparum. 
 
A   B  
Figure S1.1 Density distribution of P. vivax. (A) Pv blood-stage densities by genomic 18S rRNA copies/µl 
(log10). (B) Pv gametocytes densities by pvs25 transcript copies/µl (log10). Log10 transformations of 
copies/µl show normal distribution.  
 
A   B  
Figure S1.2 Density distribution of P. facliparum. (A) Pf blood-stage densities by genomic 18S rRNA 
copies/µl (log10). (B) Pf gametocytes densities by pfs25 transcript copies/µl (log10). Log10 transformations of 
copies/µl show almost normal distribution.  
 
A B  
Figure S1.3 Scatterplot of Pv (A) and Pf (B) blood-stage vs. gametocyte density (log10). 
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Supplementary Figure S1 
  
Figure S1. Gametocyte and overall parasite density in submicroscopic and LM-positive Pv (top) and Pf 
(bottom) infections. A. and C. Pv and Pf gametocyte densities were expressed as log10 of pvs25 and pfs25 
transcripts/µl. B. and D. Pv and Pf parasite densities were expressed as log10 of Pv- and Pf-18S rRNA gene 
copies/µl. C. and E. Pv and Pf normalized gametocyte densities. Densities were normalized by division of 
pvs25 and pfs25 transcripts/µl by Pv- or Pf-18S rRNA genomic copies/µl, respectively. 
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Supplementary Figure S2 
 
Figure S2. Gametocyte and parasite density in symptomatic and asymptomatic Pv (top) and Pf (bottom) 
infections. A. and C. Pv and Pf gametocyte densities were expressed as log10 of pvs25 and pfs25 transcripts/µl.  
B. and D. Pv and Pf parasite densities were expressed as log10 of Pv- and Pf-18S rRNA gene copies/µl. C. and E. 
Pv and Pf normalized gametocyte densities. Densities were normalized by division of pvs25 and pfs25 
transcripts/µl by Pv- or Pf-18S rRNA genomic copies/µl, respectively. 
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Supplementary Figure S3 
 
Figure S3. Gametocyte positivity and density in subsequent (i.e. not first) Pv (top) and Pf (bottom) 
infections after treatment with blood-stage anti-malarials alone (Placebo) or blood-stage anti-malarials 
plus Primaquine (PQ). A. and C. Proportion of Pv and Pf gametocyte carriers among subsequent infections by 
treatment arm. Figures within the bars indicate absolute numbers of gametocyte-positive subsequent infections 
following treatment. Error bars indicate 95% confidence intervals by Chi2 distribution. B. and E. Normalized Pv 
and Pf gametocyte densities in subsequent infections by treatment arm. Normalization was done by dividing 
pvs25 or pfs25 transcript numbers/µl by Pv- or Pf-18S rRNA copy numbers/µl. C. and F. Absolute Pv and Pf 
gametocyte densities in subsequent infections by treatment arm. Densities are expressed as log10 of pvs25 and 
pfs25 transcripts/µl. 
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General Discussion 
 
The central theme of this thesis was the molecular epidemiology and infection dynamics of 
submicroscopic and asymptomatic P. falciparum infections, whose relevance for malaria elimination 
has received much attention recently (Bousema et al., 2014; Okell et al., 2012). This chapter focuses 
on the translational research aspects of this thesis and their significance of for planning of intervention 
and surveillance strategies for malaria elimination. It further discusses limitations of this thesis and 
gives directions for future research. 
7.1 Relevance of submicroscopic and asymptomatic infections for malaria control  
Accurate estimates of malaria transmission are imperative to inform malaria control programs; 
however, the surveillance strategy used and choice of diagnostics have a major impact on the accuracy 
of the obtained estimate. Monitoring of clinical malaria cases at health facilities is easier implemented 
than active screening of large populations, but it ignores asymptomatic infections that play a major 
role in sustaining transmission (Bousema et al., 2012a; Bousema et al., 2014; Cheng et al., 2015; 
Churcher et al., 2013; Okell et al., 2009, 2012). In our study population, P. falciparum was the most 
frequent species detected in clinical cases although asymptomatic infections with P. vivax were much 
more common than with P. falciparum (chapter 3). Monitoring of clinical cases only, even if based on 
active case detection like in the Albinama cohort, thus has severe shortcomings to reflect species 
composition of the asymptomatic reservoir in settings where several species co-exist. This is because 
immunity is developed at different rate to different species (chapter 3) (Karyana et al., 2008; Koepfli 
et al., 2013; Lin et al., 2010; Maitland et al., 1996; Michon et al., 2007; Phimpraphi et al., 2008). 
Little evidence exists on the proportion of infections that remain purely asymptomatic until 
naturally cleared by the immune system and that would thus completely evade clinical surveillance. 
Longitudinal tracking of P. falciparum and P. vivax clones in the Albinama cohort allowed estimating 
the infection rate and the proportion of purely asymptomatic infections. Within eight months after the 
initial treatment, 40% and 20% of children were re-infected with P. vivax and P. falciparum¸ 
respectively, without ever presenting any symptoms, as opposed to 20% of children who became 
symptomatic (chapter 3). The majority of clones detected in samples from symptomatic malaria 
episodes were not detected previously in the same child, suggesting a recent new infection as cause for 
the episode (Figure 1). Assuming that each episode was caused by a single infecting clone, only 4% of 
849 P. vivax and 20% of 342 P. falciparum genetically distinct new infections proceeded to 
symptomatic disease. Asymptomatic infections hence make up the vast majority particularly of P. 
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vivax malaria in semi-immune school-aged PNG children, with even larger proportions to be expected 
in adults (Kasehagen et al., 2006; Koepfli et al., 2015).  
 
Figure 1. Proportion of P. falciparum and P. vivax asymptomatic clones versus clones detected in episodes 
in the Albinama study. Asymptomatic clones are defined as detected only in asymptomatic samples but not in 
an episode sample of a child. The majority of clones observed in episode samples were new infections not 
observed in the preceding samples from the same child (“new infections”). Some clones observed in episodes 
had been detected before in the same child (“persisting clones”). The proportion of asymptomatic clones versus 
clones in episodes is visualized by age group.  
 
Although long debated, it is now clear that the long-term health and societal consequences of 
chronic, asymptomatic malaria infections outweigh their potential benefits for the human host (Chen et 
al., 2016; Greenwood, 1987) such as conferring anti-malarial immunity and mitigating the severity of 
super-infections (Smith et al., 1999). Indeed, we found indications that higher exposure to P. 
falciparum conferred some protection against symptomatic P. falciparum malaria in the Albinama 
cohort; however, this did not outweigh the risks associated with frequent infection. Children living in 
the highest endemic villages still carried the main burden of disease (chapter 3). Our results therefore 
support the need for treatment of asymptomatic infections, which is increasingly appreciated as a 
cornerstone of successful malaria elimination strategies (Bousema et al., 2014; malERA Consultative 
Group on Diagnoses and Diagnostics, 2011). 
Mass drug administration (MDA) includes treatment of all asymptomatic carriers and, if high 
coverage can be achieved, may serve as a valuable elimination tool despite fears of accelerating the 
development of drug resistance (Newby et al., 2015). A variety of test-and-treat strategies are being 
evaluated to mitigate the risks of MDA (Sturrock et al., 2013), however, are intrinsically limited by the 
sensitivity of the diagnostic test used to detect low-density malaria infections (Cook et al., 2015a; 
Mosha et al., 2013; Tiono et al., 2013). RDTs are often used in test-and-treat interventions and have a 
limit of detection comparable to LM, which fails to detect half of P. falciparum infections and two 
thirds of P. vivax infections world-wide (Bousema et al., 2014; Cheng et al., 2015; Okell et al., 2009, 
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2012). Also in our cross-sectional study in high-endemic Rufiji/Tanzania, as well as in the medium-
endemic Albinama cohort in PNG, more than half of infections with P. falciparum (and P. vivax) were 
not detected by LM (chapters 2 and 3). In Rufiji, application of two ultra-sensitive qPCR assays 
uncovered a much larger extent of submicroscopic infections than previously anticipated, as almost a 
third (48/169) of submicroscopic infections were only identified by ultra-sensitive PCR but not 
standard PCR (chapter 2). Similar observations of ultra-low density infections were made for P. 
falciparum and P. vivax infections along the Thai/Myanmar border, Cambodia and Vietnam using 
high-volume blood sampling-ultra sensitive PCR (Imwong et al., 2014, 2015a, 2015b). The extent of 
asymptomatic malaria is therefore underestimated even by standard PCR, and consequentially even 
more so by RDT or LM. This casts further doubt on the usefulness of test-and-treat approaches for 
malaria elimination. Whether even more malaria infections would be found if sensitivity of detection 
increased further, and which level of sensitivity is required for sensible diagnosis of parasitemia in 
test-and-treat interventions remains to be investigated.  
The relevance of detecting and treating ultra-low density infections is questionable since 
transmission to mosquitoes occurs less frequently at low density of blood-stage parasites (Ross et al., 
2006) or gametocytes (Churcher et al., 2013) compared to high-density infections. However, until 
more is known on the fate of ultra-low density infections in the human host, aiming for the most 
sensitive detection method available seems prudent if accurate estimates of parasite prevalence are 
required.  
In their current setup, the two ultra-sensitive assays for detection of P. falciparum are mainly 
applicable for monitoring parasite prevalence in random community samples or cross sectional 
surveys in a central core facility with the required equipment. Because PCR requires DNA extraction 
and temperature cycling it is currently not applicable for point-of-care (POC) diagnosis. However, the 
rapid development of microfluidic devices (Tay et al., 2016) may soon enable field-based PCR using 
lab-on-a-chip or battery-operated devices (Nair et al., 2016) if the need for DNA extraction can be 
overcome. Alternatively, isothermal amplification methods such as LAMP seem easier field-
applicable (Cook et al., 2015b; Oriero et al., 2015), although concerns exist on the specificity and 
false-positivity rate of LAMP (Felger/Antunes-Moniz, personal communication). Other strategies aim 
at improving performance of RDT by concentration of the sample material (Pereira et al., 2015). In 
light of this variety of approaches, achieving sensitive POC malaria diagnosis seems feasible within 
the near future. These may have major implications on the design of malaria elimination strategies 
particularly in areas where emerging drug resistance renders MDA the undesired strategy towards 
screen-and-treat campaigns. 
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7.2 Evaluating heterogeneity in transmission for targeting of interventions  
Heterogeneity in malaria transmission is observed on global (Gething et al., 2011, 2012), 
regional, and local scale down to the household level in areas of unstable transmission as well as in 
high-endemic areas (Bejon et al., 2014; Gaudart et al., 2006; Hu et al., 2016; Rosas-Aguirre et al., 
2015; Sissoko et al., 2015). Different factors such as presence of water bodies and mosquito breeding 
sites, vegetation, climate, altitude, human behavioral factors, housing structure and genetic factors 
influence local malaria transmission and exposure of the individual to mosquito bites (Bousema et al., 
2012b). This heterogeneity is recognized as a major challenge to malaria control, but vice versa also 
appreciated as opportunity to maximize intervention effectiveness. This can be achieved by specific 
targeting of interventions to pockets of highest transmission that may fuel malaria transmission in a 
wider area (Bousema et al., 2012b). While theoretically promising, the evidence base comparing 
spatially targeted interventions to untargeted community-based approaches is thin. A recent cluster-
randomized controlled trial in Kenya evaluated the effects of focally targeted larviciding, LLIN 
distribution, IRS, and focal mass drug administration against the standard national malaria control 
policy and found no sustained effect on P. falciparum prevalence outside the spatial limits of the 
targeted areas (Bousema et al., 2016). Also mathematical modeling suggests that effects of vector 
control measures are higher when interventions are spatially distributed over large areas (Lutambi et 
al., 2014), and that drug campaigns are less effective when selectively targeted to high-transmission 
areas compared to untargeted approaches (Gerardin et al., 2016).  
The Albinama cohort study took place in the East Sepik/PNG approximately 2 years after a 
nationwide distribution of LLINs (Hetzel et al., 2012). P. falciparum and P. vivax transmission varied 
drastically between villages in spite of the fact that the participating children spent on average more 
than 90% of nights protected by a LLIN in all villages (chapter 3). Similar micro-geographical 
heterogeneity in malaria transmission has been described in several other studies conducted before the 
countrywide distribution of LLINs in various areas in PNG (Cattani et al., 1986; Genton et al., 1995; 
Mueller et al., 2009; Müller et al., 2003). A main challenge is explaining why this heterogeneity in 
malaria transmission can persist despite the high coverage with LLINs, and requires identifying the 
underlying patterns of human behavioral factors and vector characteristics such as species 
composition, biting behavior or vectorial capacity. This data is crucial to inform future planning of 
control strategies in PNG, which will need to address the micro-geographical differences in malaria 
transmission in absence of high-resolution data for most areas of PNG. Based on the geographical 
patterns observed in children in the Albinama cohort, where high episode incidence marked villages 
with highest transmission, reactive case detection (RCD) may be a promising approach to target 
geographically heterogeneous malaria in PNG. In RCD, clinical malaria cases presenting to a health 
facility trigger active screening of individuals living in a pre-defined radius around the origin of the 
index case and treatment of all parasite carriers. RCD has shown promising results in Zambia and 
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Swaziland (Larsen et al., 2015; Sturrock et al., 2013), but in contrast, effectiveness of RCD was 
limited in settings where exposure does not occur within the community (Hustedt et al., 2016; Littrell 
et al., 2013).  
Parasite prevalence is the most widely accepted metric to measure malaria transmission in cross-
sectional studies (Gething et al., 2011, 2012; Tusting et al., 2014), which are the most commonly 
performed type of study within malaria control programs. Other parameters such as the multiplicity of 
infection (MOI) or the proportion of single clone infections are based on parasite genotyping, and 
realistically reflect differences in malaria transmission between countries or after anti-malarial 
interventions (Anderson et al., 2000; Ibara-Okabande et al., 2012; Nkhoma et al., 2013). The 
usefulness of these three cross-sectional parameters for assessing small-scale variations in malaria 
transmission was validated in the Albinama cohort using Pf-molFOI and Pv-molFOB (after PQ 
treatment) as a longitudinal, molecular gold standard of transmission from mosquitoes. By village, P. 
falciparum parasite prevalence by PCR correlated almost perfectly with Pf-molFOI (Figure 2). Also for 
P. vivax, prevalence showed the best correlation with Pv-molFOB by village (after PQ treatment), but 
generally correlations were weaker than for P. falciparum due to the contribution of relapses that 
dampened variations in cross-sectional parameters between villages (Figure 2). Parasite prevalence by 
PCR, the easiest obtainable molecular metric in cross-sectional studies, therefore closely reflects 
small-scale variations in transmission and can be used for identifying pockets of high transmission and 
investigating the underlying factors of transmission heterogeneity.  
 
 
Figure 2. Correlation of surrogate markers of transmission by village. Prevalence, MOI and the 
proportion of single-clone infections can be assessed in cross-sectional studies. Measuring molFOI/molFOB 
requires longitudinal studies but provides more accurate estimates of transmission.  
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7.3  PQ treatment in malaria control: risks and benefits  
PQ treatment is currently advocated for two applications in malaria control: (i) for clearance of P. 
vivax and P. ovale hypnozoites and prevention of relapse, for which a 14-day administration schedule 
á 0.25 mg/kg is required (WHO, 2015); and (ii) for reduction of post-treatment P. falciparum 
gametocyte carriage using a single dose of PQ along with ACT (White, 2013; World Health 
Organization, 2015). Clinical use of PQ is severely limited due to its hemolytic effect in individuals 
with reduced activity of the red blood cell glucose-6-phosphatase dehydrogenase (G6PD) (Alving et 
al., 1956), which affects up to 30% of the population in malaria-endemic areas in Africa (Howes et al., 
2012). In PNG, the prevalence of G6PD-deficiency varies throughout the country and ranges from 1% 
along the south coast to 15% in the East Sepik (Howes et al., 2012).  
Treatment of confirmed P. vivax and P. ovale malaria in G6PD-normal patients with ACT plus 
PQ is now recommended at all endemicity levels by WHO, acknowledging a previous underestimation 
of malaria morbidity attributable to relapses (WHO, 2015). Results from the Albinama cohort support 
the validity of this revised recommendation. Our results even suggest mass drug administration of PQ 
in areas such as PNG, where the fast-relapsing tropical strain of P. vivax is endemic and relapses 
account for four out of five P. vivax infections; and where the majority of the population carries 
dormant hypnozoites (Robinson et al., 2015). The detailed investigation of patterns in malaria 
infection and disease the Albinama cohort (chapter 3) showed that frequent relapses remain the main 
source of P. vivax morbidity in 5-10 year old, semi-immune children in PNG. At this age, children in 
the East Sepik have acquired substantial clinical immunity to P. vivax over years of exposure with at 
least 5 (chapter 3, in 5-10 year old children) to 14 (Koepfli et al., 2013; in 1-4 year old children) 
genetically distinct blood-stage infections per year. Due to the genetic diversity of these past P. vivax 
infections, it is conceivable that semi-immune children in PNG may be equally able to control new P. 
vivax infections from infective bites and relapsing infections. This is because relapses are not always 
genetically identical to the primary infection but can also be meiotic siblings (Bright et al., 2014).  
Our results therefore emphasize the necessity of PQ treatment for reducing P. vivax infection and 
morbidity in PNG. Currently, the absence of a reliable and affordable RDT for G6PD deficiency 
testing as well as the poor quality of PQ available in the public as well private sector in PNG (Hetzel 
et al., 2014) are the main obstacles preventing effective treatment of the P. vivax hynozoite reservoir. 
However, new RDTs for point-of-care diagnosis of G6PD deficiency are currently being tested in field 
settings (Adu-Gyasi et al., 2015; Kim et al., 2011; Ley et al., 2015) that could be used to mitigate the 
risk of hemolysis caused by PQ treatment in health facilities or during MDA campaigns. Tafenoquine, 
an 8-aminoquilone with better efficacy than PQ, can be given as single dose and is currently being 
tested in phase 3 trials (Rajapakse et al., 2015).  In contrast to the 14-day PQ treatment regimen 
required for effective clearance of P. vivax hynozoites, the arrival of Tafenoquine would therefore 
drastically simplify the implementation of MDA using hypnozoite-clearing drugs.      
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Reducing the prevalence of P. vivax in areas where it is co-endemic with other Plasmodium 
species may have secondary effects particularly on P. falciparum infections due to altered within-host 
cross-species interactions. P. falciparum and P. vivax seem to mutually reduce prevalence of the other 
species and P. vivax infections seem to lower the risk of P. falciparum clinical disease (Mayxay et al., 
2004). Also in the Albinama cohort we observed that a concurrent P. vivax infection was associated 
with reduced P. falciparum parasite densities (chapter 3), a reduced risk for P. falciparum episodes 
(chapter 3) and reduced P. falciparum gametocyte carriage (chapter 5; similar to Koepfli et al., 2015). 
It can therefore be hypothesized that by reducing P. vivax infections in the population using intensified 
PQ treatment, P. falciparum-associated malaria episodes and P. falciparum gametocyte carriage may 
temporarily and transiently increase. However, with the drastic decline in prevalence of both species in 
PNG, mixed P. falciparum/P. vivax infections have already become highly infrequent (Hetzel et al., 
2015; Koepfli et al., 2015) and their relevance for control is thus likely to wane even more in the 
future. 
In contrast to its importance for P. vivax control, the use of PQ as gametocidal drug in treatment 
of P. falciparum malaria has to be critically reviewed. Currently, PQ is the only licensed drug for 
clearance of mature P. falciparum gametocytes, which can circulate in the blood for three to six weeks 
after clearance of asexual stages by commonly used anti-malarial drugs and thus may be transmitted to 
mosquitoes (Bousema and Drakeley, 2011; Karl et al., 2015). In Ugandan children with uncomplicated 
malaria, a single dose of PQ (at 0.4 or 0.75 mg/kg) co-administered with artemether-lumefantrine 
(AL) shortened mean post-treatment gametocyte carriage from 12 to 6 days compared to AL alone 
(Eziefula et al., 2014). However, mathematical modeling suggests that due to the short half-life of PQ, 
administrating PQ together with blood-stage treatment does not effectively reduce infectivity 
(Lawpoolsri et al., 2009). This is because no residual PQ will be present at days 7-10 after the clinical 
episode, when gametocytes that were already sequestered in the bone marrow at the time of blood-
stage treatment will be released into the blood stream (Lawpoolsri et al., 2009).  
The long maturation time of P. falciparum gametocytes is the reason why gametocyte carriage in 
symptomatic infections is often attributed not to the illness-causing infection, but rather a pre-existing 
chronic infection (Karl et al., 2016; Nacher et al., 2002; Price et al., 1999; von Seidlein et al., 2001; 
Sowunmi et al., 2004). Also in the Albinama cohort, fever was not associated with higher P. 
falciparum gametocyte positivity or density, and 79% of P. falciparum gametocyte detections 
occurred in asymptomatic infections (chapter 5). Our results therefore emphasize that single-dose PQ 
treatment of P. falciparum episodes alone is unlikely to accomplish interruption of transmission of P. 
falciparum, unless the asymptomatic reservoir is targeted simultaneously. Single-dose PQ treatment of 
P. falciparum episodes can only achieve a population-wide reduction in P. falciparum transmission if 
coverage is high and in areas where malaria infectious are predominantly symptomatic (World Health 
Organization, 2015). The impact of single-dose PQ for interruption of transmission is therefore 
Chapter 7: General Discussion 
 
166 
questionable particularly in low-transmission settings, where a large proportion of infections are 
asymptomatic (Okell et al., 2009). A recent trial in asymptomatic Ugandan children showed that 
gametocyte carriage was significantly shorter after treatment with AL plus PQ compared to AL alone; 
however, in that trial infectivity to mosquitoes was very low even after AL-only treatment (Gonçalves 
et al., 2016). This suggests that ACT treatment of asymptomatic, often low-density infections may in 
itself be sufficient to reduce gametocyte densities to sub-transmissive levels, and that the benefit of 
adding PQ to ACT treatment of asymptomatic P. falciparum malaria may be marginal. Similar 
conclusions were reached using mathematical modeling of MDA campaigns, which described that 
adding PQ to MDA with AL or dihydroartemisinin-piperaquine only conferred a small additional 
reduction in parasite prevalence in the population compared to MDA without PQ (Gerardin et al., 
2015). 
7.4  Limitations of this thesis and outlook 
7.4.1   Effects of length-dependent fragment competition during genotyping PCR 
One of the main objectives of this thesis was the determination of P. falciparum and P. vivax 
molFOI/molFOB in the Albinama cohort. Estimates of molFOI/molFOB were calculated by longitudinally 
tracking parasite clones defined by genotyping of length-polymorphic markers. However, in a later 
validation we found that length-polymorphic markers are subject to severe amplification bias during 
PCR with shorter fragments outperforming larger fragments (chapter 6). Competition between 
templates of different length was strongest between alleles of the same family and when nPCR was 
multiplexed (chapter 6). Genotyping of P. falciparum in the Albinama cohort used marker Pf-msp2 
with multiplex nPCR, which in light of our validation was suboptimal for detection of minority clones. 
Marker Pv-msp1F3 for genotyping of P. vivax infections in the Albinama cohort possesses only one 
allelic family, leading to direct competition of all alleles. Allele sizes of Pv-msp1 (147-445bp) were 
comparable to Pf-msp2 (206-619bp), and hence the amplification bias during Pv-msp1F3 nPCR is 
likely similar or even more severe compared to Pf-msp2 nPCR, for which two allelic families exist. 
Amplification of Pv-msp1F3 in a multiplex pPCR with alternative marker Pv-MS16 may have further 
aggravated bias during PCR. However, our validation showed that template competition was almost 
completely abrogated between Pf-msp2 alleles of different families when nPCRs were performed as 
simplex PCRs (chapter 6). This indicates that all alleles were amplified during pPCR and that template 
competition occurs mainly during extensive re-amplification in nPCR. Also an earlier analysis of Pf-
msp2 and Pv-msp1F3 clone detectability using the same PCR protocols found similar minority clone 
detectability for both markers (Pf-msp2, 79%; Pv-msp1F3, 73%; Koepfli et al., 2011). P. vivax 
infections were generally characterized by lower parasite density and higher number of concurrent 
clones compared to P. falciparum infections in the Albinama cohort (chapter 3), which may have led 
to lower P. vivax minority clone detectability relative to P. falciparum.  
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However, the fact that molFOI/molFOB are obtained from a longitudinal sequence of samples may 
reduce the impact of bias during PCR on estimates of molFOI/molFOB. Clone composition in chronic 
infections likely varies between subsequent samples, with some infections being cleared and others 
newly establishing themselves in the blood stream. Furthermore, fluctuations in clonal density during 
the course of an infection may lead to detection of different majority clones in consecutive samples, 
even if overall the same clones are present. When several consecutive samples are concerned, failure 
to detect an infecting clone may be attributable more to the frequency of sampling versus infection 
duration (chapter 4). In addition, the discriminatory power of the genotyping marker due to dominant 
alleles (>20% of allele detections as observed for Pf-msp2 and Pv-msp1F3 in the Albinama cohort) 
may have a more substantial effect on molFOI/molFOB estimates than bias during PCR, as re-infections 
with the same genotype will go undetected.   
Nonetheless, in light of the pitfalls of length polymorphic markers, research should be intensified 
on alternative genotyping methods based on single-nucleotide-polymorphisms such as barcoding 
(Galinsky et al., 2015), high-resolution melt curve analysis (Daniels et al., 2015) or next-generation 
sequencing (Campino et al., 2011). Next-generation sequencing-based methods are particularly 
promising because they allow high-throughput parallel genotyping of several markers in hundreds of 
samples. In large surveillance studies, drug resistance markers could possibly be included along with 
genotyping markers without an increase in cost. However, the relative limit of detection of minority 
clones using deep sequencing remains to be validated, especially when amplification reactions are 
multiplexed. 
7.4.2   Detection of ultra-low density P. vivax infections 
Due to the characteristic lower density of P. vivax compared to P. falciparum infections, ultra-
sensitive assays for reliable detection of low-density P. vivax infections would be of great use for both 
surveillance as well as monitoring of intervention efficiency. Identification of multi-copy sequences in 
the P. vivax genome suitable for qPCR design, similar to the TARE-2 and varATS assays developed 
for P. falciparum (chapter 2), was not successful within the framework of this thesis. No telomeric 
repeat structures have been described for P. vivax (Carlton et al., 2008), and no repeats were found by 
searching the P. vivax telomeres of strain Sal1 (http://plasmodb.org) and the recently available P01 
isolate (http://www.genedb.org/ Homepage/PvivaxP01) using repeat finder software. Vir/pir genes, 
ortholog to P. falciparum var genes, are a multi-gene family with 346 members that are grouped into 
12 clusters based on amino acid sequence homology (Lopez et al., 2013; Merino et al., 2006; del 
Portillo et al., 2001). Although the presence of a conserved transmembrane domain has been described 
(Carlton et al., 2008), DNA sequences of vir/pir genes exhibited only little conservation between 
clusters, thereby impeding the design of primers that amplify several clusters. Also within clusters, 
vir/pir DNA sequences were too variable even for degenerate primer design. Other multi-gene families 
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exist in P. vivax, but comprise less than 56 members (Tachibana et al., 2012) with low DNA sequence 
conservation.  
Similar to P. falciparum, targeting P. vivax mitochondrial DNA may increase PCR sensitivity 
(Putaporntip et al., 2011). Indeed, this strategy seemed promising in initial experiments, but was not 
pursued further due to time constraints. Finally, RNA-based detection of highly abundant 18S rRNA 
transcripts in P. vivax infections may be a valuable alternative to DNA based detection. Due to the 
lower parasite densities and thus lower abundancy of P. vivax 18S rRNA transcripts compared to P. 
falciparum, this strategy may be less prone to cross-contamination between samples, which is one of 
the major drawbacks of P. falciparum RNA-based detection (Wampfler et al., 2013). Nonetheless, 
RNA-based detection requires more elaborate sampling strategy, extraction method, sample handling 
and storage compared to DNA-based detection. The design of a robust, ultra-sensitive assay for 
detection of P. vivax, preferentially DNA-based, therefore remains a major challenge for future 
research.   
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